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resumo 
 
 
A mitocôndria desempenha um papel fundamental na regulação de vários 
processos celulares, com particular relevância na produção de energia, sendo 
a β-oxidação mitocondrial dos ácidos gordos uma das vias metabólicas que 
tem lugar neste organelo. Os défices da β-oxidação mitocondrial dos ácidos 
gordos estão entre os grupos de doenças metabólicas mais estudados, 
existindo contudo, algumas questões que continuam por esclarecer, como a 
sua prevalência ao nascimento em determinadas regiões da Europa e quais e 
de que forma os vários determinantes patofisiológicos interatuam para produzir 
um determinado fenótipo. 
A análise dos dados de programas de rastreio neonatal da península Ibérica 
possibilitou estimar a prevalência ao nascimento dos défices da β-oxidação 
mitocondrial, tendo-se observado um dos valores mais elevados 
(particularmente em Portugal) no âmbito das regiões europeias, 
fundamentalmente devido à grande prevalência ao nascimento dos défices da 
desidrogenase dos ácidos gordos de cadeia média. Estes resultados realçam o 
impacto deste grupo de doenças genéticas nesta região europeia. 
A caracterização do proteoma mitocondrial, a partir de fibroblastos em cultura, 
de doentes com défices da β-oxidação mitocondrial (especificamente défice 
múltiplo das desidogenases (MADD) e défice da desidrogenase dos ácidos 3-
hidroxilados de cadeia longa (LCHADD)) permitiu obter uma perspetiva geral 
sobre a plasticidade do proteoma mitocondrial nestas doenças assim como 
avaliar quais as principais vias metabólicas envolvidas na sua patogénese. Em 
formas severas de MADD foi observada uma sobre-expressão de chaperones, 
enzimas antioxidantes e proteínas associadas à apoptose. Nestas células foi 
igualmente observada a sobre-expressão de enzimas glicolíticas, como 
adaptação ao bloqueio da β-oxidação. A análise de amostras de doentes com 
LCHADD também evidenciou uma sobre-expressão de enzimas glicolíticas, 
assim como de proteínas relacionadas com a apoptose, e a modulação do 
sistema de defesa antioxidante. O doente com uma forma severa de LCHADD 
apresentou níveis de stress oxidativo elevados, associados a uma sobre-
expressão da MnSOD, enquanto o doente com uma forma moderada 
apresentou níveis mais baixos de stress oxidativo e uma sub-expressão da 
MnSOD. Estes resultados são provavelmente o reflexo do papel da MnSOD na 
regulação dos níveis de ROS, mantendo-os em níveis que não provoquem 
danos, mas que permitam iniciar processos de sinalização com vista à 
manutenção celular. A comparação de forma moderadas com severas de 
MADD não revelou diferenças significativas, muito provavelmente porque os 
níveis de stress oxidativo são suficientemente altos para despoletar uma 
resposta semelhante às formas severas. Os presentes resultados realçam as 
diferenças na modulação do sistema de defesa antioxidante no espectro dos 
défices da β-oxidação mitocondrial. 
No seu conjunto os resultados obtidos revelam as principais vias moduladas 
nos défices da β-oxidação mitocondrial e a importância do stress oxidativo e 
sistema de defesa antioxidante para o fenótipo. Ao permitem compreender 
melhor a complexa interação entre os vários fatores que interagem com vista 
ao fenótipo e que podem ser de origem genética, epigenética ou ambiental, 
contribuem para o desenvolvimento de novas e mais eficazes abordagens 
terapêuticas. !
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abstract 
 
Mitochondria are central organelles for cell survival with particular relevance in 
energy production and signalling, being mitochondrial fatty acid β–oxidation 
(FAO) one of the metabolic pathways harboured in this organelle.  
FAO disorders (FAOD) are among the most well studied inborn errors of 
metabolism, mainly due to their impact in health. Nevertheless, some questions 
remain unsolved, as their prevalence in certain European regions and how 
pathophysiological determinants combine towards the phenotype. 
Analysis of data from newborn screening programs from Portugal and Spain 
allowed the estimation of the birth prevalence of FAOD revealing that this group 
of disorders presents in Iberia (and particularly in Portugal) one of the highest 
European birth prevalence, mainly due to the high birth prevalence of medium 
chain acyl-CoA dehydrogenase deficiency. These results highlight the impact of 
this group of genetic disorders in this European region. 
The characterization of mitochondrial proteome, from patients fibroblasts with 
FAOD, namely multiple acyl-CoA dehydrogenase deficiency (MADD) and long 
chain acyl-CoA dehydrogenase deficiency (LCHADD), provided a global 
perspective of the mitochondrial proteome plasticity in these disorders and 
highlights the main molecular pathways involved in their pathogenesis. Severe 
MADD forms show an overexpression of chaperones, antioxidant enzymes 
(MnSOD), and apoptotic proteins. An overexpression of glycolytic enzymes, 
which reflects cellular adaptation to energy deficiency due to FAO blockage, 
was also observed. When LCHADD fibroblasts were analysed a metabolic 
switching to glycolysis was also observed with overexpression of apoptotic 
proteins and modulation of the antioxidant defence system. Severe LCHADD 
present increased ROS alongside with up regulation of MnSOD while moderate 
forms have lower ROS and down-regulation of MnSOD. This probably reflects 
the role of MnSOD in buffering cellular ROS, maintain them at levels that allow 
cells to avoid damage and start a cellular response towards survival. When 
ROS levels are very high cells have to overexpress MnSOD for detoxifying 
proposes. When severe forms of MADD were compared to moderate forms no 
major differences were noticed, most probably because ROS levels in 
moderate MADD are high enough to trigger a response similar to that observed 
in severe forms. Our data highlights, for the first time, the differences in the 
modulation of antioxidant defence among FAOD spectrum. 
Overall, the data reveals the main pathways modulated in FAOD and the 
importance of ROS levels and antioxidant defence system modulation for 
disease severity. These results highlight the complex interaction between 
phenotypic determinants in FAOD that include genetic, epigenetic and 
environmental factors. The development of future better treatment approaches 
is dependent on the knowledge on how all these determinants interact towards 
phenotype.!!!
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1. General introduction 
 
Mitochondria are crucial cellular organelles, which play a central role in energy production, 
being also deeply involved with intracellular signalling (Benard and Rossignol 2008). One 
of the main metabolic pathways that take place at mitochondria is fatty acid β-oxidation 
(FAO), which has a particular importance in energy production during periods of fasting or 
metabolic stress (Rinaldo, Matern et al. 2002). The oxidation of fatty acids molecules will 
result in the production of NADH and FADH2, that will channel their electrons to oxidative 
phosphorylation (OXPHOS) for ATP production, and acetyl-CoA molecules that can be 
further oxidized via Krebs cycle or enter ketogenesis for ketone bodies production (Houten 
and Wanders 2010). 
To accomplish its function FAO involves the coordinate action of about 25 distinct 
mitochondrial proteins, among enzymes and transporters. Deficiencies in several of these 
proteins have been associated to human diseases, the mitochondrial fatty acid β-oxidation 
disorders (FAOD), which include at least 15 distinct genetic disorders (Rinaldo, Matern et 
al. 2002, Vockley and Whiteman 2002, Kompare and Rizzo 2008, Moczulski, Majak et al. 
2009). The clinical presentation associated to FAOD is very heterogeneous and may 
include hypoketotic hypoglycemia, Reye-like syndrome, cardiomyopahy, myopathy or 
rhabdomyolysis, with also heterogeneous degrees of severity, which can range from 
asymptomatic patients to neonatal sudden death, being acute episodes triggered by 
fasting or illness (Rinaldo, Matern et al. 2002). Treatment of FAOD relies mainly on 
avoiding fasting and diets supplemented with alternative fuel sources, like carbohydrates 
or medium chain fatty acids (Kompare and Rizzo 2008). 
For a long time efforts have been made to understand the molecular basis underlying the 
observed clinical variability, which is noticed even between patients with the same 
genotype. It is believed that the pathophysiology of FAOD mainly relies on the resulting 
energy deficiency, on the accumulation of toxic metabolites, the shortness of vital 
components, altered enzyme products, loss of protein/protein interactions and in the 
accumulation of misfolded proteins (Gregersen and Olsen 2010, Olpin 2013). The 
contribution of each of these factors to the phenotype is different for each FAOD, 
depending on the defective protein, the nature of the mutation and the interaction of these 
determinants with other cellular and environmental factors.  The ways all these disease 
determinants interact towards phenotype development are still poorly understood and it’s 
! 4!
believed that study approaches like global proteomics will give a polygenic perspective, 
helping to understand it. 
 
2. State of the art 
 
2.1 Mitochondrial fatty acid β-oxidation 
Fatty acids are a group of biological molecules characterised by a long hydrocarbon chain 
and a terminal carboxylate group. They play several important roles as they are key 
components of the cell membrane, enzymes and hormones, being also, alongside with 
carbohydrates and amino acids, one of the major energy sources in many organisms, 
including mammals (Moczulski, Majak et al. 2009).  In the cells, fatty acids can undergo 
different oxidative degradation processes, namely alpha (α), beta (β) and omega (ω) 
oxidation, depending on the carbon involved in the oxidation process (Moczulski, Majak et 
al. 2009).  The α-oxidation of fatty acids occurs in the peroxisomes and in humans is used 
to remove a single carbon from the carboxyl end of phytamic acid, that cannot undergo β-
oxidation due to its β-methyl branch, transforming it into pristamic acid, which can; the ω-
oxidation occurs in the endoplasmatic reticulum and is a minor pathway that only 
becomes relevant when β-oxidation is defective; the β-oxidation represents the major 
process by which fatty acids are oxidised, by a sequential removal of a two carbon units 
from the acyl chain, and takes place in the peroxisomes and in the mitochondria (Bartlett 
and Eaton 2004). 
The β-oxidation of fatty acids is a key metabolic pathway for energy homeostasis in 
organs such as the liver, heart and skeletal muscle, being of particular importance in 
periods of fasting, high energy demanding as exercise, febrile illness or metabolic stress 
(Rinaldo, Matern et al. 2002). While in the heart and the skeletal muscle β-oxidation acts 
exclusively as a source of ATP, in the liver it also serves a different role by providing 
ketone bodies (acetoacetate and β-hydroxybutyrate) to peripheral tissues like the kidney 
(Thumelin, Forestier et al. 1993), the small intestine (Bekesi and Williamson 1990), white 
adipose tissue (Thumelin, Kohl et al. 1999) and the brain (Cullingford, Dolphin et al. 
1998), that are ketogenic under certain circumstances, namely when glucose levels are 
low. The oxidation of long-chain fatty acids also provides the energy required for non-
shivering thermogenesis by brown adipose tissue (Mitchell and Fukao 2006). 
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Georg Franz Knoop first discovered fatty acid β-oxidation, back in 1904 (Knoop 1904). By 
feeding dogs with different types of fatty acids, namely odd and even fatty acids, and then 
analysing the resulting metabolic products in dogs urine, he noticed that when the dogs 
were fed with odd chain fatty acids, hippuric acid was found in urine, and when the dogs 
were fed with even chain fatty acids phenaceturic acid was excreted. So he concluded 
that the metabolism of fatty acids proceeds by a successive removal of two carbon 
molecules and as the remaining fatty acids has to contain a carboxylic group. He also 
proposed that the oxidation took place in the β carbon atom (Knoop 1904). 
The β-oxidation takes place in the peroxisomes and in the mitochondria where the 
oxidation of the fatty acids involves similar enzymatic steps (dehydrogenation, hydration, 
another dehydrogenation and finally a thiolytic cleavage) (Wanders, van Roermund et al. 
2003, Houten and Wanders 2010). Besides these similarities major differences exist 
between the β-oxidation in both organelles, specifically in pathway regulation and 
substrates oxidised by each of the systems. While mitochondria β-oxidise palmitic acid, 
oleic acid and linoleic acids, the major fatty acids from diet, in the peroxisomes are 
oxidised a range of fatty acids and fatty acids derivatives that are not handled by 
mitochondria. These include very-long-chain fatty acids, pristamic acid and the bile acid 
intermediates, di- and trihydroxycholestanoic acid (Wanders and Waterham 2006). 
Quantitatively, most of the β-oxidation of fatty acids occurs in mitochondria, representing 
peroxisomal β-oxidation no more than 10% of the β-oxidation flux of long-chain-fatty-acids 
(Eaton 2002). The differences between the two β-oxidation systems are clear in the 
different clinical presentations of the patients affected by either a mitochondrial or 
peroxisomal β-oxidation defects (Rinaldo, Matern et al. 2002, Wanders and Waterham 
2006). In this work we will focus on the mitochondrial β-oxidation of fatty acids. 
So that the fatty acids (FA) can be fully β-oxidised in mitochondria, in order to originate 
ATP and/or ketone bodies, some sequential steps must be completed:  
i. Transport of FA across the plasma membrane 
ii. Transport of FA across the mitochondrial membrane – carnitine shuttle 
iii. Mitochondrial β-oxidation cycles. 
Each of these essential steps will now be presented. 
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2.1.1 Transport of FA across the plasma membrane 
Long chain fatty acids represent the main source of energy for many organs and since 
most tissues contain only small amounts of storage lipids, they depend on a continuous 
supply of FA, mostly from adipose tissue (Rinaldo, Matern et al. 2002). FA are released by 
the action of lipases and then transported through the blood bounded to albumin to 
ensure solubility (Kerner and Hoppel 2000). Tissues then take them up by tissue-specific 
fatty acid transporters (Berk and Stump 1999), although passive uptake probably also 
occurs (Houten and Wanders 2010). 
Fatty acid transport proteins (FATPs) are transmembrane proteins responsible for the 
uptake of very-long and long chain FA into the cell. In Humans, the family of FATPs 
encompass a group of six highly homologous proteins: FATP1 to FATP6, which are tissue 
specific. FATP1 (SLC27A1) and FATP4 (SLC27A4) are expressed in the skeletal muscle; 
in the heart are expressed FATP6 (SLC27A6) and FATP1 (SLC27A1); whereas in the liver 
it is FATP5 (SLC27A5) that plays a crucial role in the uptake of FA (Gimeno, Ortegon et al. 
2003, Doege and Stahl 2006). Besides FATPs other proteins, like fatty acid translocase 
and plasma membrane fatty acid binding protein are also involved in FA uptake (Glatz, 
Bonen et al. 2006, Kiens 2006). 
FATPs have not only a transport function but they also have acyl-CoA synthetase activity, 
which suggests that FA are rapidly converted to their activated form – acyl-CoA’s – once 
inside the cell, allowing them to participate in metabolic processes and drive the process 
(Houten and Wanders 2010). The activation of FA consists in the join of the FA to the SH 
group of CoenzymeA (CoA) through a thioester linkage (R-CO-SCoA), a high energy 
bound (Figure 1). 
 
R-COOH + CoA-SH + ATP    ⇔    R-CO-SCoA + AMP + PPi 
 
Figure 1: Activation reaction of fatty acids. 
Fatty acid activation is an energy dependent reaction that consists in linking a coenzyme 
A molecule to the fatty acid, through a thioester linkage. 
R-COOH, fatty acid; CoA-SH, coenzyme A; ATP, adenosine triphospate; R-CO-SCoA, 
activated fatty acid; AMP, adenosine monophosphate; PPi, inorganic pyrophosphate. 
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The subsequent hydrolysis of PPi drives the reaction in the forward direction, maintaining 
a low cytosolic free fatty acid content (Moczulski, Majak et al. 2009). Nevertheless, the 
activation of FA is not exclusively performed by FATPs, being generally accepted that FA 
activation is also done by several acyl-CoA synthetases protein families which reside in 
the membrane of the mitochondria, peroxisomes and endoplasmic reticulum (Watkins 
2008). While very long and long chain fatty acids are activated out of the mitochondria, 
medium and short chain fatty acids, are thought to directly enter to the mitochondrial 
matrix, being activated already inside mitochondria (Vockley and Whiteman 2002). 
In order to stabilize and ensure FA solubility in the cytoplasm a group of binding proteins a 
is needed, the so called cytoplasmic fatty acid binding proteins (FABPs) (Schaap, Binas et 
al. 1999, Binas, Han et al. 2003, Erol, Kumar et al. 2004). These proteins are involved in 
reversibly binding intracellular hydrophobic ligands and trafficking them throughout cellular 
compartments, including the peroxisomes, mitochondria, endoplasmic reticulum and 
nucleus (Smathers and Petersen 2011). So far 9 different FABPs, with tissue-specific 
distribution, have been identified: L (liver), I (intestinal), H (muscle and heart), A 
(adipocyte), E (epidermal), Il (ileal), B (brain), M (myelin) and T (testis) (Chmurzynska 
2006). 
2.1.2 Transport of FA to the mitochondrial matrix 
After FA activation, the resulting very long and long acyl-CoA esters cannot pass through 
the mitochondrial wall (Kerner and Hoppel 2000). Two membranes compose 
mitochondrial wall: the mitochondrial outer membrane (MOM) and the mitochondrial inner 
membrane (MIM), being the latter non-permeable to FA, more precisely to very long and 
long chain FA. In order to overpass this a shuttle is required – the carnitine shuttle (figure 
2). 
The carnitine shuttle is a mitochondrial membrane transport system that uses carnitine to 
assist FA transport, being its availability a crucial factor for FA transport. Carnitine (3-
hydroxy-4-trimethylaminobutirate) (figure 3) can be obtained from the diet or through 
biosynthesis. In omnivorous Humans, the diet accounts for about 75 % of the body 
carnitine, being biosynthesis important in situations where diet cannot supply enough 
carnitine (Vaz and Wanders 2002). The substrate for the biosynthesis of carnitine is 6-N-
trimethyl-lysine, that is a product of lysosomal and proteosomal degradation of proteins 
containing N-methylated lysines. Carnitine biosynthetic pathway involves a series of four 
enzymatic steps that take place mainly in the liver and in the kidneys (Vaz, Melegh et al. 
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2002, Strijbis, Vaz et al. 2010). Independently from its origin, and so it can reach tissues, 
carnitine must be actively transported through the plasma cell membrane. This transport is 
done by tissue specific plasma membrane carnitine transporters, which allow that 
carnitine concentration in the cytoplasm of cells to be as 50 times higher than the 
concentration in the plasma (Bremer 1983). Muscle, heart and renal tubes express 
OCTN2, the well-known plasma membrane carnitine transporter, while the liver expresses 
a different one (Nezu, Tamai et al. 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Representation of mitochondrial fatty acid β-oxidation machinery.  
A schematic representation mitochondrial fatty acid β-oxidation pathway is shown. This 
mitochondrial pathway is responsible for the oxidation of fatty acids and encompasses the 
carnitine shuttle (CPT-1, CACT and CPT-2), that enables the transport of fatty acids to the 
mitochondrial matrix, and the β-oxidation cycles that oxidise the fatty acids to acetyl-CoA, 
with NADH and FADH2 production. 
CPT-1, carnitine palmitoyl transferase I; CPT-2, carnitine palmitoyl transferase II; CACT, 
carnitine-acylcarnitine translocase; MOM, mitochondrial outer membrane; MIM, 
mitochondrial inner membrane; VLCAD, very long chain acyl-CoA dehydrogenase; MTP, 
mitochondrial trifunctional protein; MCAD, medium chain acyl-CoA dehydrogenase; CoA, 
coenzyme A; MCKAT, medium chain 3-ketoacyl-CoA thiolase; SCEH, short chain 2-enoyl-
CoA hydratase; M/SCHAD, medium/short chain 3-hydroxyacyl-CoA dehydrogenase; 
SCAD, short chain acyl-CoA dehydrogenase. 
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Figure 3: Structural formula of the carnitne molecule. 
The carnitine shuttle involves the concerted action of a group of three proteins: carnitine 
palmitoyl transferase I (CPT I); Carnitine-acylcarnitine translocase (CACT); and carnitine 
palmitoyl transferase II (CPT II), all membrane bound (Kerner and Hoppel 2000) (Figure 
2). CPT I is the first player in the shuttle catalyzing the formation of acylcarnitines from 
acyl-CoA’s plus carnitine. It is a true transmembrane protein located in the MOM having 
its active and regulatory sites facing the cytosol (Kerner and Hoppel 2000).  CPT I is the 
only enzyme of the mitochondrial β-oxidation that is known to exist in tissue specific 
isoforms: a liver type (CPT Ia), a muscle type (CPT Ib) and a brain type (CPT Ic) 
(Bonnefont, Djouadi et al. 2004). Although called liver type, CPT Ia is also expressed in 
the brain, kidney, lung, spleen, intestine, pancreas, ovary and fibroblasts, while CPT Ib is 
expressed in heart, skeletal muscle and testis (Houten and Wanders 2010). Type Ic is 
brain specific and its function still needs to be addressed (Bonnefont, Djouadi et al. 2004). 
After the formation of the acylcarnitines they are transported through the MIM by the 
action of CACT, a transmembrane protein, that exchanges acylcarnitine by a free carnitine 
molecule, from the mitochondrial matrix. The carnitine cycle is completed by the action of 
CPT II that is embedded in the MIM, with its active site facing the mitochondrial matrix, 
and that reverts the action of CPT I, hydrolyzing the acylcarnitines back to acyl-CoAs and 
free carnitine. The reaction catalysed by CPT II is reversible, as well as the CACT 
transport, allowing acylcarnitine export to the cytoplasm. 
The resulting acyl-CoAs are now in the mitochondrial matrix and can undergo chain 
shortening through the β-oxidation cycles. 
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2.1.3 Mitochondrial β-oxidation cycles 
Once inside the mitochondrial the activated form of the FA can now be fully oxidized to 
water and CO2, by the action of β-oxidation, in tight collaboration with the Krebs cycle and 
mitochondrial respiratory chain. Mitochondrial β-oxidation is a cyclic pathway and FA will 
be subject to several oxidation cycles, that consist in the sequential occurrence of four 
enzymatic reactions, resulting in the removal of a two carbon molecule – acetyl-CoA, per 
cycle and leading to the correspondent chain shortening of the FA (Houten and Wanders 
2010) (figure 4). The resulting acetyl-CoA molecule will be the substrate for the 
ketogenesis and/or be fully oxidised by the Krebs cycle, while the resulting FA will be 
subject to more β-oxidation cycles until the formation of two acetyl-CoA molecules in the 
last cycle (Houten and Wanders 2010). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Reactions of the mitochondrial fatty acid β-oxidation cycles. 
Mitochondrial β-oxidation cycles encompass a series of four sequential reactions: a 
dehydrogenation, a hydration, another dehydrogenation and finally a thiolytic cleavage. 
The result of each cycle is the formation of one FADH2 and one NADH molecules as well 
as the release of an acetyl-CoA, alongside with the shortening of the oxidised fatty acid.  
FAD, flavin adenine dinucleotide; FADH2, flavin adenine dinucleotide – reduced form; 
NAD, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide – 
reduced form; CoA, coenzyme A. 
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The β-oxidation cycle’s reactions initiate by a dehydrogenation of the acyl-CoA ester to 
yield a trans-2-enoyl-CoA. This reaction involves several members of the acyl-CoA 
dehydrogenase family of FAD- requiring oxidoreductases (Rinaldo, Matern et al. 2002, 
Moczulski, Majak et al. 2009, Houten and Wanders 2010). These dehydrogenases are 
chain specific: very-long chain acyl-CoA dehydrogenase (VLCAD) (from C12 to C18), 
medium chain acyl-CoA dehydrogenase (MCAD) (from C6 to C10) and short chain acyl-
CoA dehydrogenase (SCAD) (from C4 to C6) (Rinaldo, Matern et al. 2002). Another 
dehydrogenase, long chain acyl-CoA dehydrogenase (LCAD) has also been reported has 
having a chain length specificity between MCAD and VLCAD, although its role in fatty acid 
β-oxidation is unclear, due to its low expression levels (Kurtz, Rinaldo et al. 1998, Vockley 
and Whiteman 2002, Chegary, Brinke et al. 2009).  
This second reaction involves the hydration of the double bound in the 2,3 position to 
produce a stereo specific L-3-hydroxyacyl-CoA species. This reaction is catalysed either 
by long-chain-enoyl-CoA-hydratase (LCEH) or by short chain-enoyl-CoA-hydratase 
(SCEH), also known as crotonase, which is responsible for the hydration of medium and 
short chain enoyl-CoA species (Kanazawa, Ohtake et al. 1993).  
The third step consists in another dehydrogenation reaction to produce 3-keto-acyl-CoA 
molecules from the L-3-hydroxyacyl-CoA’s. This reaction is catalysed either by long chain-
3-hydroxy-acyl-CoA dehydrogenase (LCHAD), responsible for the reduction of long chain 
substrates, or by medium/short-chain-3-hydroxy-acyl-CoA dehydrogenase (M/SCHAD), 
with a broad chain length specificity and responsible by the reduction of medium and short 
chain L-3-hydroxyacyl-CoA’s (Rinaldo, Matern et al. 2002, Vockley and Whiteman 2002, 
Moczulski, Majak et al. 2009, Houten and Wanders 2010). 
The fourth and final step of the β-oxidation cycle is a thiolytic cleavage of the 3-keto-acyl-
CoA to produce a two carbon chain shortened acyl-CoA plus an acetyl-CoA molecule. 
This final step is catalysed by long chain 3-ketoacyl-CoA thiolase (LCKAT) and medium 
chain 3-ketoacyl-CoA thiolase (MCKAT) (Rinaldo, Matern et al. 2002, Vockley and 
Whiteman 2002, Moczulski, Majak et al. 2009, Houten and Wanders 2010). 
As a result of each complete cycle an acetyl-CoA molecule, a NADH, a FADH2, and the 
shortened acyl-CoA molecule are formed. The reminiscent acyl-CoA enters another cycle, 
and so on until the formation of two acetyl-CoA molecules in the last cycle. Acetyl-CoA 
can have several metabolic fates, including entering Krebs cycle, for complete oxidation 
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and production of more reducing power (NADH) and ketogenisis. NADH and FADH2 will 
deliver their electrons to the respiratory chain for ATP production (Houten and Wanders 
2010) (figure 5). 
 
 
 
 
 
Figure 5: Representation of the relation between mitochondrial fatty acid β-
oxidation, Krebs cycle (tricarboxylic acid cycle - TCA) and OXPHOS. 
Mitochondrial fatty acid β-oxidation acts in close relation with other mitochondrial 
pathways in particular Krebs cycle and OXPHOS. NADH and FADH2 produced during the 
β-oxidation cycles will deliver their electron at complex I and ubiquinone, respectively, for 
ATP production, while acetyl-CoA can be used as ketogenesis substrate or be fully 
oxidised at Krebs cycle with further production of NADH/FADH2 molecules.  
LC, long chain fatty acids; CoA – coenzyme A; CPT I; carnitine palmitoyl transferase I; 
CPT II, carnitine palmitoyl transferase II; CACT, carnitine-acylcarnitine translocase; 
VLCAD; very long chain acyl-CoA dehydrogenase; MTP, mitochondrial trifunctional 
protein; MC, medium chain fatty acids; MCKAT, medium chain 3-ketoacyl-CoA thiolase; 
MCAD, medium chain acyl-CoA dehydrogenase; SCAD, short chain acyl-CoA 
dehydrogenase; M/SCHAD, medium/short chain 3-hydroxyacyl-CoA dehydrogenase; TCA 
cycle, tricarboxylic acid cycle; ETF, electron transfer flavoprotein; ETF:QO, Electron 
transfer flavoprotein – ubiquinone oxidoreductase; FAD, flavin adenine dinucleotide; 
FADH2, flavin adenine dinucleotide – reduced form; I, NADH dehydrogenase; II, succinate 
dehydrogenase; III, ubiquinone:cytochrome c oxidoreductase; IV, cytochome oxidase; V, 
ATP synthase. 
 
After reaching the mitochondrial matrix long-chain acyl-CoA’s are first metabolised by 
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delivers three enzymatic activities: LCHAD, LCEK and LCKAT. MTP has a hetero-octamer 
structure, consisting in four α-subunits and four β-subunits, encoded by the HADHA 
(OMIM# 600890) and HADHB (OMIM# 143450) genes respectively, both located in the 
same region of chromosome 2p23 (Ushikubo, Aoyama et al. 1996). The α-subunit 
contains the long-chain enoyl-CoA hydratase (LCEH) and long-chain 3-hydroxyacyl-CoA 
dehydrogenase activities (LCHAD), while the β-subunit contains the long-chain 3-
ketothiolase activity (LCKAT) (Vockley and Whiteman 2002).  
After two or three cycles the resulting medium chain acyl-CoA’s are metabolised by a 
group of enzymes, which are believed to be harboured in the matrix: MCAD, SCAD, 
M/SCHAD, MCKAT and crotonase (Rinaldo, Matern et al. 2002, Houten and Wanders 
2010). 
FA with an odd number of carbons are degraded in the same way, but the product of the 
last turn is propionyl-CoA, which is converted in succinyl-CoA that enters the Krebs cycle 
(Moczulski, Majak et al. 2009). The oxidation of monounsaturated FA requires the 
intervention of another mitochondrial enzyme, the decenoyl-CoA delta isomerase (3,2-
trans-enoyl-CoA isomerase), while for the oxidation of polyunsaturated fatty acids another 
enzyme is also needed – 2,4-dienoyl-CoA reductase (Vockley and Whiteman 2002). 
The resulting NADH molecules will deliver their electrons to the respiratory chain at the 
complex I (NADH dehydrogenase) level while FADH2 will channel their electrons through 
the electron transfer flavoprotein complex to ubiquinone (Houten and Wanders 2010). The 
electron transfer flavoprotein complex is composed by two proteins: electron-transfer-
flavoprotein: ubiquinone oxidoreductase (ETF:QO) and electron-transfer-flavoprotein 
(ETF). ETF is a mitochondrial matrix heterodimer with two subunits (α and β), containing 
one flavinadenine nucleotide (FAD) and one adenosine monophosphate, per molecule 
(Roberts, Frerman et al. 1996). ETF:QO is integrated in the MIM and contains one FAD 
molecule and a 4Fe4S cluster (Simkovic, Degala et al. 2002). These two proteins of the 
complex act coordinately to efficiently transfer the electrons from at least 11 
dehydrogenases to ubiquinone, and recover the pool of FAD molecules inside the 
mitochondria (Schiff, Froissart et al. 2006).  
To complete the mitochondrial β-oxidation of fatty acids, it is necessary the intervention 
and coordinated action of about 25 different proteins (table 1) 
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Table 1: Proteins involved in mitochondrial fatty acid oxidation 
Metabolic process Protein Abbreviation 
Fatty acid transport and activation Fatty acid transporter(s) FATP(s) 
 Acyl-CoA synthetase(s) --- 
   
Carnitine Uptake Organic cation transporter 2 (plasma membrane carnitine transporter) OCTN2 
   
Carnitine cycle Carnitine palmitoyl transferase I (liver) lCPT I (CPT I) 
 Carnitine palmitoyl transferase I (muscle) mCPT I 
 Carnitine palmitoyl transferase I (brain) bCPT I 
 Carnitine palmitoyl transferase II  CPT II 
 Carnitine acyl-carnitine translocase CACT 
   
Mitochondrial β-oxidation spiral Very long chain acyl-CoA dehydrogenase VLCAD 
 ACAD-9 ACAD-9 
 Long chain acyl-CoA dehydrogenase LCAD 
 Medium chain acyl-CoA dehydrogenase MCAD 
 Shot chain acyl-CoA dehydrogenase SCAD 
 Trifunctional protein MTP 
 Long chain 3-hydroxyacyl-CoA dehydrogenase LCHAD 
 Long chain 2-enoyl-CoA hydratase LCEH 
 Long chain 3-ketoacyl-CoA thiolase LCKAT 
 Short chain 2-enoyl-CoA hydratase (crotonase) SCEH 
 Medium/short chain 3-hydroxyacyl-CoA dehydrogenase M/SCHAD 
 Medium chain 3-ketoacyl-CoA thiolase MCKAT 
   
Enzymes of β-oxidation of 
unsaturated fats Long chain Δ
3, Δ2- noyl-CoA isomerase --- 
 Short chain Δ3, Δ2- noyl-CoA isomerase --- 
 2,4 – dienoyl-CoA reductase --- 
   
Electron transfer Electron transfer flavoprotein ETF 
 ETF-ubiquinone oxidoreductase ETF-QO 
 
Although some FAO proteins are associated with/embedded in the MIM, like CPT II, 
VLCAD or MTP, and others believed to be in the mitochondrial matrix (like for example 
MCAD and SCAD), for the pathway to work efficiently all players in the sequentially 
processing of FAO substrates must be spatially organized in the so called FAO 
metabolome (Gregersen and Olsen 2010). Some hypotheses were raised on the 
organization of FAO metabolome, but common to all is the need of a close relation 
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between FAO proteins as well as a tight relation with other mitochondrial pathways, in 
particular the respiratory chain (Gregersen and Olsen 2010) (figure 6). 
  
 
 
 
 
 
 
 
 
                          
Figure 6: Hypothesis for the structural organisation of the FAO metabolome 
(adapted from (Gregersen and Olsen 2010)) 
For the efficient function of mitochondrial fatty acid β-oxidation a close spatial relation 
between all components is hypothesised. The proposed organization will maximise 
substrate channelling and pathway efficiency. 
CI, NADH dehydrogenase; CIII, ubiquinone:cytochrome c oxidoreductase; CPT 2, 
carnitine palmitoyl transferase II; Q10, ubiquinone; VLCAD; very long chain acyl-CoA 
dehydrogenase; MTP, mitochondrial trifunctional protein; LCAD, long chain acyl-CoA 
dehydrogenase; MCAD, medium chain acyl-CoA dehydrogenase; SCAD, short chain acyl-
CoA dehydrogenase; ETF, electron transfer flavoprotein; ETF:QO, Electron transfer 
flavoprotein – ubiquinone oxidoreductase; EH, enoyl hydratases; KT, 3-keto acyl-CoA 
thiolases; HAD, 3-hydroxy acyl-CoA dehydrogenases. 
 
Due to the central role of mitochondrial fatty acid β-oxidation on cellular metabolism and 
to its relations with other metabolic pathways, it is subjected to tight metabolic control.  
 
HAD$
KT$
ETF)Q
O$
CIII$
CI$
EH$
ET
F$
VLCAD$
CPT2$
Q10$
ETF$
ETF$
ETF$
LCAD$
M
CAD
$SC
AD
$
M
TP$
EH$ KT$
HAD$
EH$KT$
HAD$
! 16!
2.1.4. Regulation of mitochondrial fatty acid β-oxidation 
The various tissues are to some extent flexible in the choice of the substrate they will use 
for energy production. In the majority of the tissues glucose is the first choice in the well-
feed state, being the oxidation of fatty acids and ketone bodies more important during 
fasting. This relationship between the oxidation of glucose and fatty acids is known as the 
Randle cycle (Hue and Taegtmeyer 2009). Nevertheless, there are tissues that don’t 
follow this logic in terms of fuel utilization. In the muscle the choice of substrate is complex 
and dependent on the type and duration of exercise. If the exercise is more intense and 
so more ATP needs to be available in a short period of time, then glucose is the choice, 
but on the other hand FAO is used at is maximum at moderate exercise intensity (Schulz 
1994).  
Nevertheless, the main determinant of which substrate oxidase to produce energy is its 
availability, with hormones playing a key role in the process (Hue and Taegtmeyer 2009). 
Insulin is secreted by pancreas in response to high plasma glucose concentrations, 
stimulating those pathways involved in glucose oxidation and storage (ex. glycolysis and 
glycogenesis), limiting fatty acid oxidation by inhibiting lipolysis. On the other hand, during 
periods of fasting, hormones like glucagon, adrenaline, noradrenaline and 
adrenocorticotropic hormone induce lipolysis and fatty acid utilization (Hue and 
Taegtmeyer 2009). 
Free fatty acids (FFA) themselves also have a role in the regulation of the metabolic flux 
through FAO, but in a long-term perspective, since they affect the transcription of genes 
encoding for several of the FAO proteins. FFA stimulates the peroxisome proliferator 
activator receptor (PPAR), a transcription regulator, being the regulation of FAO by 
PPAR’s a subject of intensive research in recent years (Djouadi and Bastin 2008). The 
relation was first established when Gulick and collaborators (Gulick, Cresci et al. 1994) 
showed that PPAR could increase the transcription of MCAD. The molecular mechanism 
was then elucidated; including the identification of the specific DNA sequence which 
allows binding of the activated PPAR on the promoter of the targeted gene (Gulick, Cresci 
et al. 1994). Three different isoforms were identified in Humans: PPAR α, PPAR δ and 
PPAR ϒ. PPAR ϒ is strongly expressed in the adipose tissue regulating the synthesis and 
storage of FA, but not affecting the enzymes involved in their oxidation (Djouadi and 
Bastin 2008). PPAR α and PPAR δ were shown to play important roles in FAO regulation 
in different tissues, regulating the expression of several FAO proteins, with PPAR α 
having particular importance in regulating energy metabolism in the liver where it is 
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abundantly expressed (Djouadi and Bastin 2008). But all regulation mechanisms that rely 
on manipulation of gene transcription are always considered long-term processes. 
Mechanisms of short-term control of pathways usually are based on the modulation of the 
activity of key enzymes of the pathways, normally the rate limiting steps.  
CPT I is the key control point of FAO (Drynan, Quant et al. 1996). Modulating CPT I 
activity the amount of acylcarnitines produced will be controlled and, as a consequence, 
the FA transport to the mitochondria that will regulate the flux through the pathway. CPT I 
activity is regulated by its inhibitor malonyl-CoA, which binds the enzyme in a binding site 
that faces the cytoplasm (McGarry and Foster 1980, Saggerson 2008).  Malonyl-CoA is 
not only an intermediate in the pathway of de novo fatty acid biosynthesis and fatty acid 
elongation, but also has important signalling functions through its allosteric inhibition of 
CPT I (McGarry and Foster 1980, Saggerson 2008). The amount of malonyl-CoA inside 
the cell reflects the availability of acetyl-CoA, the end product of FAO and the substrate for 
malonyl-CoA production, but also ATP, since the activity of acetyl-CoA carboxylase 
requires ATP to convert acetyl-CoA into malonyl-CoA. In this way, cellular availability of 
acetyl-CoA and ATP will shut down FAO (figure 7).! 
 
 
 
 
 
 
 
 
                             
Figure 7: Control effect of malonyl-CoA over CPT1. 
The amount of malonyl-CoA represents acetyl-CoA and ATP availability, being a key 
energy status sensor, and will regulate the metabolic flux through mitochondrial fatty acid 
β-oxidation by inhibiting CPT 1. 
LCFA, long chain fatty acids; TG, triglycerides; CPT 1, carnitine palmitoyl transferase I 
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Although less important, there are other forms of FAO control, as for example redox 
control (based on the ratio NAD+/NADH), feedback control (inhibition of the acyl-CoA 
dehydrogenases by their products and thiolases by acetyl-CoA) and availability of 
carnitine and CoA (Eaton 2002). 
 
2.2. Mitochondrial fatty acid β-oxidation disorders  
From the about 25 proteins, including enzymes and transport proteins, that must act co-
ordinately to complete FAO, deficiencies in many of them are associated to Humans 
diseases. Mitochondrial fatty acid β-oxidation disorders (FAOD) are a group of inherited 
metabolic disorders, transmitted in an autosomal recessive pattern, which affect the 
oxidative metabolism of FA. FAOD are included in the group of diseases of the energetic 
metabolism, alongside with for example glycogen storage diseases and respiratory chain 
deficiencies. 
FAO defects are known since 1973, when DiMauro described carnitine palmitoyl-CoA 
transferase II deficiency (DiMauro and DiMauro 1973) and since then several defects 
affecting the carnitine cycle as well as the acyl-CoA dehydrogenases activities were 
identified. Nowadays, about 15 mitochondrial FAO defects are known (Rinaldo, Matern et 
al. 2002, Vockley and Whiteman 2002, Kompare and Rizzo 2008, Moczulski, Majak et al. 
2009) (table 2).  
Deficient activity of another acyl-CoA dehydrogenase - ACAD 9, has been associated to 
disease, nevertheless its role in FAO is not fully elucidated (He, Rutledge et al. 2007). It is 
supposed that it acts as a chaperonin in the oxidative phosphorylation (OXPHOS) 
complex I, with yet unknown effect of FAO (Haack, Danhauser et al. 2010, Scheffler 2010, 
Gerards, van den Bosch et al. 2011, He, Pei et al. 2011). 
In general, FAOD may present three different clinical presentations. The first one, the 
more severe and often lethal, has a predominant hepatic presentation that usually 
appears during infancy or in the neonatal period with severe hypoketotic hypoglycemia 
and Reye-like syndrome. This clinical presentation is usually triggered by a catabolic state 
associated for example to infections. The second type of clinical presentation includes the 
appearance, during infancy, of cardiac symptoms such as dilated or hypertrophic 
cardiomyopathy and/or arrhythmias.  The third and last group includes the patients that 
present a milder and late on set disease, usually characterised by exercise induced 
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myopathy and rhabdomyolysis (Wanders, Vreken et al. 1999, Rinaldo, Matern et al. 
2002). Some of the severe forms can present a combination of the symptoms presented 
above. FAOD have also been associated to sudden infant death syndrome (SIDS) 
(Lundemose, Kolvraa et al. 1997, Lovera, Porta et al. 2012) and maternal liver disease 
during pregnancy (acute fatty liver in the pregnancy  (AFLP) and hemolysis, elevated liver 
enzymes and low platelets (HELLP) syndrome) (Browning, Levy et al. 2006, Ibdah 2006, 
Gutierrez Junquera, Balmaseda et al. 2009, Rector and Ibdah 2009). 
 
Table 2: Defects of the mitochondrial fatty acid β-oxidation.  
Deficient protein Gene Gene locus First described OMIM 
     
FATP(s) ---- --- 1998(Odaib, 
Shneider et al. 1998) 
600691 
OCTN2 SLC22A5 5q33 1975(Karpati, 
Carpenter et al. 
1975) 
212140 
     
CPT I CPT1A 11q13 1981(Bougneres, 
Saudubray et al. 
1981) 
255120 
CPT II CPT2 1p32 1973(DiMauro and 
DiMauro 1973) 
25510/600649/ 
668836 
CACT SLC25A2 3p21 1992(Stanley, Hale 
et al. 1992) 
212138 
     
VLCAD ACADVL 17p11 1993(Bertrand, 
Largilliere et al. 
1993) 
201475 
MTP HADHA 2p23 1992(Jackson, Kler 
et al. 1992, 
Wanders, L et al. 
1992) 
609015 
 HADHB 2p23 --- --- 
LCHAD (isolated) HADHA 2p23 1989(Wanders, 
Duran et al. 1989) 
609016 
LCKAT (isolated) HADHB 2p23 2006(Das, Illsinger 
et al. 2006) 
143450 
MCAD ACADM 1p31 1976(Gregersen, 
Lauritzen et al. 
1976) 
201450 
SCAD ACADS 12q22 1984(Amendt, 
Greene et al. 1987) 
201470 
SCHAD HADHSC 4q25 1991(Tein, De Vivo 
et al. 1991) 
231530 
MCKAT --- --- 1997(Kamijo, Indo et 
al. 1997) 
602199 
     
2,4 – dienoyl-CoA reductase DECR1 8q21 1990(Roe, Millington 
et al. 1990) 
222745 
     
 ETF (MADD) ETFA 15q23 1976(Przyrembel, 
Wendel et al. 1976) 
231680 
 ETFB 19q13 --- --- 
ETF-QO (MADD) ETFDH 4q32 --- --- 
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A block in the FAO pathway usually results in a characteristic biochemical phenotype of 
hypoketotic hypoglycemia due to the shortage of acetyl-CoA, that is not only the substrate 
for ketogenisis but also a stimulating factor for pyruvate carboxylase, which will limit 
gluconeogenesis (Houten and Wanders 2010). Moreover, FAO malfunction will increase 
glucose oxidation, further contributing for hypoglycemia (Houten and Wanders 2010). 
However, in some cases, low blood sugar may not become evident until the metabolic 
crisis is well developed (Roe 2002, Olpin 2004). Another consequence of FAOD is the 
development of secondary hyperammonaemia, due to the decreasing availability of N-
acetylglutamate, compromising the efficiency of the urea cycle (Moczulski, Majak et al. 
2009).  
In this group of inherited metabolic disorders, the severity of the symptoms covers a wide 
range that goes from neonatal sudden death to asymptomatic adults and there are 
overlapping phenotypes between the various enzyme defects. Moreover, the same 
defective enzyme may be associated with considerable clinical heterogeneity (Sim, 
Hammond et al. 2002). If not early treated, these disorders usually result in significant 
morbidity and mortality with some deceasing during acute episodes and those who don’t 
may suffer from irreversible neurological trauma (Kompare and Rizzo 2008).  
The main characteristics of the most common FAOD are now presented. 
 
2.2.1 Carnitine Uptake Defect  
Carnitine uptake defect (CUD) or primary carnitine deficiency (MIM# 212140), is caused 
by a defective OCTN2 transporter, and is characterised by carnitine loss due to defective 
renal reabsorption and depleted tissue levels of carnitine to a point that compromises the 
transport of long chain FA to the mitochondria (Vockley and Whiteman 2002). Plasma 
carnitine levels are extremely low or even undetectable in these patients. The clinical 
presentation can range from undiagnosed, almost asymptomatic, adults (mostly mothers 
detected through differential diagnosis of abnormal newborn screening results of their 
sons) (Lee, Tang et al. 2010) to presentations that include a progressive cardiac failure 
and skeletal muscle weakness. Hypoketotic hypoglycemia and coma may also be seen 
during periods of catabolic stress, mainly in the first months of life (Rinaldo, Matern et al. 
2002, Vockley and Whiteman 2002). Treatment is based on L-carnitine supplementation 
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in order to restore intracellular carnitine levels, being treatment response very good as 
well as the clinical outcome (Rinaldo, Matern et al. 2002). 
2.2.2 CPT I deficiency  
Deficiency in any of the proteins of the mitochondrial carnitine shuttle compromises the 
transport of long chain FA to the mitochondria. Deficiency in CPT I (MIM# 255120) doesn’t 
allow the formation of long chain acylcarnitines, and so their transport for the 
mitochondrial matrix. Although CPT I exists in three isoforms in Humans – liver, muscle 
and brain, only deficiencies in the liver type (CPT Ia) are known to cause disease 
(Moczulski, Majak et al. 2009). Clinical symptoms are mainly characterised by Reye-like 
attacks with hypoketotic hypoglycemia, beginning in infancy and multi organ failure. 
Muscle and cardiac symptoms although rare, have already been reported (Moczulski, 
Majak et al. 2009). Patients also present hyperammonaemia and very elevated free 
carnitine in plasma, alongside with very low acylcarnitines, being the most characteristic 
biochemical feature of this FAOD. Treatment is mainly based on avoiding fasting with 
frequent feedings, high carbohydrate/low fat diet and supplementation with medium chain 
triglycerides, since medium chain FA don’t require CPT I to enter mitochondria (Kompare 
and Rizzo 2008). 
2.2.3 CACT deficiency  
CACT deficiency (MIM# 212138) generally presents with chronic progressive liver 
disease, servere hypoketotic hypoglycemia and cardiac arrhythmias and/or hypertrophy 
usually enhanced by intercurrent illness (Bonnet, Martin et al. 1999, Lopriore, Gemke et 
al. 2001). Hyperammonaemia is in this FAOD more frequent and skeletal myopathy is 
also a common feature. A few patients with milder phenotypes have been reported and 
biochemically, patients present low free carnitine and increase of long chain acylcarnitines 
(Vockley and Whiteman 2002). Treatment is based on avoiding fasting, frequent meals, 
high carbohydrate/low fat diet and supplemented with medium chain triglycerides 
(Kompare and Rizzo 2008). 
2.2.2. CPT 2 deficiency  
CPT II deficiency (MIM# 255110/600649/608836) is one of the most frequent disorders 
affecting FAO (Kompare and Rizzo 2008). In CPT II deficiency, long chain acylcarnitines 
are translocated to the mitochondrial matrix, but then they are not hydrolysed to acyl-CoA 
plus carnitine, compromising its oxidation. The hallmarks of this FAOD are the muscle 
symptoms that classically present in late childhood or early adulthood as recurrent 
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episodes of myoglobinuria following prolonged exercise, fasting, high fat intake, fever, 
viral infection or even emotional stress (Vockley and Whiteman 2002). Rhabdomyolisis 
can be severe enough to lead to acute renal failure. There is no tendency to 
hypoglycemia and patients are usually well between episodes. Three phenotypes of 
different severity can be identified: an adult onset, an infantile and a neonatal form, that 
are probably due to different levels of residual activity of the deficient enzyme (Moczulski, 
Majak et al. 2009). While the most common adult forms only have the typical muscular 
presentation, the infantile form may present with recurrent liver failure, hypoketotic 
hypoglycemia, leading sometimes to coma. It is a frequent cause of SIDS due to 
paroxysmal heartbeat and Reye-like syndrome (Fontaine, Briand et al. 1998). The most 
severe neonatal form present a multiple organ failure and all affected children die shortly 
after birth (Pollitt 1993). The phenotypic presentation can be highly variable even within 
the same family (Bonnefont, Demaugre et al. 1999). Biochemically, patients present with 
low free carnitine and increase of long chain acylcarnitines exactly as CACT patients and 
diagnosis must be clarified by direct enzyme or molecular analysis (Moczulski, Majak et 
al. 2009). Treatment depends on the severity of the clinical presentation with infantile 
forms requiring intravenous glucose during acute episodes. Diet should be based on a 
high carbohydrate/low fat diet, supplemented with medium chain triglycerides, avoid 
fasting and vigorous exercise (Kompare and Rizzo 2008). 
2.2.5 VLCAD deficiency  
VLCAD deficiency (VLCADD; MIM#201475) results in impaired ability to oxidise long-
chain fatty acids (Voermans, van Engelen et al. 2006). It is commonly associated with an 
early onset of cardiac and skeletal myopathy, although hypoketotic hypoglycemia, 
hyperammonemia and liver failure also occur (Aoyama, Souri et al. 1995). The clinical 
presentation is then very heterogeneous, with a severe type that has an onset in the 
neonatal period with hypertrophic cardiomyopathy and hypoketotic hypoglycemia, being 
often fatal; a late onset infantile form presents with fasting hypoketotic hypoglycemia and 
lethargy, but without cardiomyopathy; at last a milder late onset form with a debut usually 
after adolescence, with predominant muscle involvement – exercise induced 
rhabdomyolysis and myoglobinuria (Doi, Abo et al. 2000, Hoffman, Steiner et al. 2006, 
Voermans, van Engelen et al. 2006). Treatment includes avoiding fasting, high 
carbohydrate diet and medium chain triglycerides supplementation when needed 
(situations of high energy demand) and carnitine supplementation (Kompare and Rizzo 
2008). 
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Biochemically these patients are characterized by an accumulation of long chain 
acylcarnitines in blood, in particular tetradecenoylcarnitine (C14:1) (Kompare and Rizzo 
2008). 
2.2.6 MTP deficiencies 
The mitochondrial trifunctional protein, an enzymatic complex bound to the mitochondrial 
inner membrane, catalyzes the last three of the four chain-shortening reactions in the 
mitochondrial β-oxidation of long chain fatty acids.  
Distinct autosomal recessive disorders of fatty acid oxidation are associated to different 
degrees of MTP malfunction. Two groups first described general MTP deficiency 
independently in 1992 (Jackson, Kler et al. 1992, Wanders, L et al. 1992), which is 
defined by reduced activity of all three MTP enzymes and can be caused by a 
heterogeneous group of mutations in any of the HADHA or HADHB genes. Besides 
general MTP deficiency, isolated enzymatic defects were identified, namely LCKAT and 
LCHAD deficiencies, since no isolated LCEH deficient patient has been identified so far. 
Isolated LCKAT deficiency has only been reported in very few patients and associated to 
mutations in HADHB gene (Das, Illsinger et al. 2006), but isolated LCHAD deficiency 
(LCHADD), although rare, is the most common defect of the MTP complex (Rinaldo, 
Matern et al. 2002). Isolated LCHADD was first described in 1989 (Wanders, Duran et al. 
1989) and is biochemically characterized by a reduced LCHAD activity with substantial 
preservation of the other two MTP enzymatic activities (>60% of the normal)(Olpin, Clark 
et al. 2005). This fatty acid oxidation pathway block results in the accumulation of long-
chain 3-hydroxy fatty acids and their metabolites. 
LCHADD is associated to mutations in the HADHA gene, in particular to c.1528G>C 
(p.Glu474Gln), in the exon 15, that is present in 56% (Ibdah, Bennett et al. 1999) to 
87%(Ijlst, Ruiter et al. 1996) of the mutated alleles. This common mutation is located in 
the active site of LCHAD, compromising its activity but not affecting the normal levels of 
expression of the α-subunit neither the functional structure of the MTP complex, which 
results in nearly normal activities of LCEH and LCKAT (Barycki, O'Brien et al. 1999, 
Rector, Payne et al. 2008). Patients homozygous for c.1528G>C have undoubtedly 
isolated LCHADD deficiency, although patients heterozygous for the common mutation 
and for other on the α-subunit can have isolated LCHADD or general MTP deficiency, 
depending on the nature of the second mutation, being patients classification only 
accessed based on the enzymatic activities measurements (Diekman, Boelen et al. 2013). 
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Since it was first described in 1989 (Wanders, Duran et al. 1989), LCHADD is recognized 
as one of the most severe fatty acid oxidation disorders and besides the reduced genetic 
heterogeneity, due to the occurrence of a very common frequent mutation, LCHADD 
presents with heterogeneous phenotypes (den Boer, Wanders et al. 2002). Clinical 
manifestations can vary from early onset cardiomyopathy, hypoketotic hypoglycemia, 
hepatopathy (sometimes presenting as Reye like syndrome), coma and sudden death, to 
a later onset with myopathy, progressive neuropathy and pigmentary retinopathy (den 
Boer, Wanders et al. 2002). Current management relies mainly on fasting avoidance. 
Generally a low-fat, high carbohydrate diet is instituted alongside with the possibility of 
medium chain fatty acid supplementation (Spiekerkoetter, Lindner et al. 2009). 
The presence of retinopathy is exclusive of MTP deficiencies, among the group of fatty 
acid oxidation disorders, and it is also documented that women who carry fetus with MTP 
defects (general or isolated) often develop AFLP and HELLP syndrome (Rector and Ibdah 
2009). The severity and the particular features of the clinical presentations of isolated 
LCHADD are related with the pathomechanisms of this fatty acid oxidation disorder. It is 
believed that besides the energy deficiency, the toxic accumulation of 3-hydroxy fatty 
acids (3-hydroxydodecanoic, 3-hydroxytetradecanoic and 3-hydroxypalmitic acids) plays a 
key role on disease development (Ventura, Ruiter et al. 2005, Bennett 2010, Olpin 2013). 
These toxic 3-hydroxyacil metabolites are believed to be the cause of retinopathy 
development and progressive neuropathy (Tein, Vajsar et al. 1999). It was reported that 
accumulated fatty acids might play a role inducing oxidative stress (Tonin, Ferreira et al. 
2010) and compromise OXPHOS activity (Tonin, Amaral et al. 2013). Nevertheless, we 
can’t still explain why LCHADD patients, homozygous for the common mutation, can 
present so differently with some exhibiting significant morbidity, developing 
chorioretinopathy and neuropathy while others reach adulthood with minimal retinal 
changes as the only manifestations of the clinical disease (Spiekerkoetter and Wood 
2010, Olpin 2013).  
2.2.7. MCAD deficiency  
The MCADD (MIM#201450) phenotype ranges from asymptomatic to Reye-like syndrome 
presentations and sudden death (Leydiker, Neidich et al. 2011, Lovera, Porta et al. 2012). 
Typical clinical presentation consists of a metabolic crisis, characterized by hypoketotic 
hypoglycemia, lethargy, coma, seizures or sudden death, and triggered by catabolic 
stress during fasting or illness (Hoflack, Caruba et al. 2010, Yusupov, Finegold et al. 
2010). The disease usually manifests in the first few years, although presentations in 
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adulthood has also been described (Yang, Ding et al. 2000, Wilcken, Haas et al. 2007). 
Unusual manifestations, such as neonatal ventricular tachyarrhythmias (Maclean, Rasiah 
et al. 2005, Rice, Brazelton et al. 2007, Yusuf, Jirapradittha et al. 2010) and pulmonary 
haemorrhage(Maclean, Rasiah et al. 2005) have also been reported. The risk of 
neurological impairment after an acute metabolic decompensation is high (Grosse, Khoury 
et al. 2006). MCAD protein is encoded by the ACADM gene, located on chromosome 
1p31. More than 80 mutations have been identified in this gene, most of which are 
missense mutations (Stenson, Ball et al. 2003). Approximately 80% of patients diagnosed 
clinically are homozygous for the common c.985A>G mutation (Waddell, Wiley et al. 
2006, Hsu, Zytkovicz et al. 2008). Patients with the same genotype and belonging to the 
same family can present very distinct clinical presentations, with the occurrence of 
asymptomatic adults and SIDS cases within the same family. Biochemically, these 
patients present an elevation of medium chain acylcarnitines in blood. Treatment is mainly 
based on avoiding fasting (Kompare and Rizzo 2008). 
2.2.8. SCAD deficiency 
SCAD deficiency (SCADD; MIM#201470) impairs the last β-oxidation cycles, those where 
short-chain fatty acids are involved. There is a huge debate on whether this deficiency is 
really a disease or not (Jethva and Ficicioglu 2008). Clinical symptoms are very 
heterogeneous ranging from asymptomatic individual (mainly detected in newborn 
screening programs) to others that present clinically with episodic hypoglycemia with 
ketosis or with developmental delay. The presence of hypotonia, muscle weakness and 
seizures has also been reported (Gregersen, Andresen et al. 2001, Gregersen, Andresen 
et al. 2008, Jethva and Ficicioglu 2008). Biochemically they present an elevation of C4-
carnitine in blood and increased ethylmalonic acid in urine. Treatment, when applied, is 
based on avoidance of fasting in periods of metabolic stress (Kompare and Rizzo 2008). 
2.2.9. SCHAD deficiency  
Medium and short-chain L-3-hydroxyacyl-CoA dehydrogenase (M/SCHAD, SCHAD) 
catalyzes the penultimate step in FAO, the NAD+ dependent conversion of L-3-
hydroxyacyl-CoA to 3-ketoacyl-CoA for medium- and short-chain acyl-CoA intermediates 
(C4-C12). The clinical phenotype of most patients that have been described with SCHAD 
deficiency (MIM#231530) is recurrent hypoglycemia associated with hyperinsulinism 
(Clayton 2001, Eaton, Chatziandreou et al. 2003, Molven, Matre et al. 2004). The 
mechanism of hyperinsulinism has been identified as loss of a non-enzymatic inhibitory 
effect of the SCHAD protein on glutamate dehydrogenase (GDH) – moonlighting effect. In 
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the absence of SCHAD protein, this inhibition is lost resulting in gain of activity of GDH 
and increased release of insulin, similar to that seen in patients with gain of function 
mutations in GDH (Li, Chen et al. 2010). Treatment includes diazoxide to control insulin 
secretion (Kompare and Rizzo 2008). 
2.2.10. Multiple Acyl-CoA dehydrogenation deficiency  
Multiple Acyl-CoA dehydrogenation deficiency, also known as glutaric aciduria type II 
(MADD; MIM#231680), is an autosomal recessive disorder that affect fatty acids, amino 
acids and choline metabolism, caused by defects in one of the two flavoproteins – ETF or 
ETF-QO, or in yet unidentified disturbances of riboflavin metabolism (Vockley and 
Whiteman 2002). In mitochondria, ETF receives electrons from several mitochondrial 
flavin-containing dehydrogenases, which are transferred to ETF-QO and subsequently 
passed to ubiquinone in the respiratory chain (Houten and Wanders 2010). ETF exists in 
the mitochondrial matrix as a heterodimer of alpha and beta subunits, while ETF-QO is a 
monomer embedded in the inner mitochondrial membrane (Gregersen and Olsen 2010). 
A deficiency in either ETF or ETF-QO will result in a secondary malfunction of all the 11 
flavoprotein dehydrogenases that use ETF complex to channel the electrons resultants 
from dehydrogenation reactions to OXPHOS (Watmough and Frerman 2010)  
Clinically, MADD patients can be classified into three phenotypic groups: neonatal onset 
forms, with (type I) or without (type II) congenital abnormalities and late onset forms (type 
III) (Schiff, Froissart et al. 2006). Neonatal onset forms are characterised by severe 
nonketotic hypoglicemias, hypotonia, failure to thrive, hyperamonaemia, metabolic 
acidosis and usually lead to an early death. Patients with late onset forms manifest 
proximal myopathy, hepatomegaly and encephalopathy usually associated with 
intermittent vomiting, abdominal pain, hypoglycemia and lethargy (Vockley and Whiteman 
2002).  
MADD is caused by mutations in the genes ETFA, ETFB and ETFDH, which encode ETF 
alpha subunit, ETF beta subunit and ETF-QO (Gregersen, Andresen et al. 2001, Olsen, 
Olpin et al. 2007). It was also observed some degree of genotype/phenotype correlation, 
with null mutations associated to neonatal onset form, and mutations that lead to the 
retention of some residual activity of the enzyme, associated to type III phenotypes 
(Olsen, Andresen et al. 2003, Gregersen, Bross et al. 2004). It was also realised that 
many of these patients, mainly type III, are responsive to riboflavin (riboflavin responsive 
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MADD; RR-MADD) treatment, with a significant positive effect on symptoms and 
metabolic control (Gregersen 1985). 
For many years it was believed that the riboflavin responsive form of the disease was due 
to an inborn error affecting FAD cofactor formation from riboflavin (vitamin B2) 
(Gregersen, Wintzensen et al. 1982, Rhead, Roettger et al. 1993). Only when Olsen and 
collaborators, in 2007, reported that the majority of patients have molecular lesions on 
ETFDH gene, it became clear that this is the main cause of RR-MADD (Olsen, Olpin et al. 
2007). All RR-MADD patients have at least one missense mutation on ETFDH gene, on or 
near the FAD – binding or ubiquinone-binding domains (Cornelius, Frerman et al. 2012). 
Nevertheless, very recently, genetic defects affecting riboflavin metabolism and transport 
were identified in a few RR-MADD patients (Green, Wiseman et al. 2010, Johnson, Gibbs 
et al. 2010, Bosch, Abeling et al. 2011, Ho, Yonezawa et al. 2011) 
The mechanisms underlying riboflavin responsiveness in RR-MADD patients with ETFDH 
mutations, only very recently were described (Cornelius, Frerman et al. 2012). It was 
demonstrated that riboflavin response results from the ability of the FAD to promote the 
folding of the variant protein, stabilize their mature protein or folding intermediates 
(Cornelius, Frerman et al. 2012). MADD treatment is based on a fat restricted diet, 
sometimes with supplementation with coenzyme Q10 and riboflavin. 
One important data to evaluate the health impact of a disorders or a group of disorders in 
a given population is its prevalence. Given the difficulties in calculating accurate 
epidemiological data based on symptomatic diagnosed patients, assessment of the true 
birth prevalence of FAOD is only possible through NBS data.  
The knowledge on the birth prevalence of FAOD in a defined population is important so 
follow-up and public health policies can be properly defined and implemented. More 
robust data still require for some European populations, namely Iberia, where the only 
publication is from 2010, reporting the data from the screening of about 300000 
Portuguese newborns and where FAO present a birth prevalence of 1:6325  (Vilarinho, 
Rocha et al. 2010). 
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2.3. Pathophysiology of mitochondrial fatty acid β-oxidation disorders 
FAOD present a wide clinical phenotype spectrum that results from the interaction 
between genetic determinants and environmental factors, which act together towards the 
phenotype. Realising how all these players interact is the key to better understand this 
group of disorders and ultimately to the development of new and more effective treatment 
approaches. In this way, disclosing the pathophysiology of FAOD as well as molecular 
mechanisms underlying the observed clinical variability has gained importance in the last 
years, supported by innovative technological developments. 
2.3.1 Phenotype determinants 
Since the advances of molecular biology, in late 80’s, and the discovery of a growing 
number of genes in the 90’s, the study of the relationship between genotypes and 
phenotypes in genetic diseases become a main goal for the genetic community, in order 
to elucidate the pathophysiology and so predict the clinical outcome and improve 
treatment and diagnosis. Inborn errors of metabolism and more precisely FAOD were not 
an exception. Soon was realized that the initial naive idea that genetic information was the 
key answer to all questions, was an oversimplification of the system. The effect of genetic 
mutations and their interaction with other genes and other cellular/environmental factors 
was shown not to be straightforward in all situations. Nevertheless, it was possible to 
establish, for some genetic disorders some degree of correlation between the mutation 
and phenotype, with some examples between FAOD. 
For some FAOD, namely CPT2, VLCADD and MADD, it is possible to establish a certain 
degree of relation between the nature of the molecular lesion, the residual enzymatic 
activity and the clinical phenotype. Complete enzymatic deficiencies, associated to severe 
mutations (nonsense, frameshift and splice site mutation resulting in mRNA degradation 
and protein absence) are associated with severe clinical disease while some missense 
mutations and small in frame deletions and insertions were associated to milder clinical 
presentations (Andresen, Olpin et al. 1999, Gregersen, Andresen et al. 2001, Olpin, Afifi 
et al. 2003, Olsen, Andresen et al. 2003). On the contrary, on FAOD affecting the 
oxidation of medium/short chain FA (MCADD and SCADD) it is not possible to establish 
any genotype/phenotype correlation (Gregersen, Andresen et al. 2001, Gregersen, 
Andresen et al. 2008, Arnold, Saavedra-Matiz et al. 2010). Even in the disorders in which 
it is possible to establish a correlation between the genotype and the phenotype it is not 
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possible to justify some of the differences observed between individual with milder forms 
(Olpin, Afifi et al. 2003). 
Mutations in another genes coding to related proteins (from the same pathway or at least 
related to the deficient protein) have the power to modulate phenotypic expression of the 
disease. Supporting this idea is the concept of “synergistic heterozygocity”. Synergistic 
heterozygocity relies on the hypothesis that individuals that are heterozygous carriers for 
mutations in multiple genes coding for proteins in the same metabolic pathway or 
functionally related pathways, have a cumulative effect that cause a physiologically 
relevant reduction of the flux through the metabolic pathway (Vockley, Rinaldo et al. 2000, 
Vockley 2008, Zschocke 2008). There are reported cases of CPT2 carriers that present 
clinical symptoms, and in some of these it was demonstrated the presence of mutation(s) 
in another related genes (Vladutiu, Bennett et al. 2000, Vockley, Rinaldo et al. 2000, 
Vladutiu 2001, Vladutiu, Bennett et al. 2002). 
So, phenotypic variability can, to some extent, be justified by the genotype, but many 
questions remain unsolved, namely those related to the interaction between genetic, 
epigenetic and environmental factors. 
Energy depletion as a result of a FAO blockage is the most well known determinant of 
disease phenotype, but it is far from being the only one. Biochemical consequences of a 
FAOD can be grouped in six different categories (adapted from Olpin, 2013 (Olpin 2013)): 
1-Inadequate supply of energy 
In order to understand the pathophysiology of FAOD it is important not to forget the key 
importance of this metabolic pathway in energy production, where it participates in about 
80% of ATP production during fasting (Olpin 2013). Deficient energy supply, namely 
during periods of high demand (as fasting, febrile illness, gastrointestinal illness, cold 
exposure or muscular exertion) is of major importance for triggering symptom 
development, reflecting the clinical signs tissue needs at the time of the metabolic stress. 
This way, in FAOD, when energy restriction is due to fasting, hepatic function will most 
probably be affected with less impact on skeletal and cardiac muscle function. On the 
other hand, if the stressor is exercise it is most likely to have an effect on muscles and 
myopatic signs are expected (Bennett 2010). It is believed that energy deficiency will have 
more impact in FAOD affecting the oxidation of long chain FA than in those affecting 
medium and short chain FA, because in the last ones there is a partial oxidation of long 
chain FA that will result in some energy production (Bennett 2010). 
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In the fasting liver, gluconeogenesis and ketogenesis are stimulated to provide energy for 
both hepatic and extra hepatic tissues. In the presence of a FAOD, there is a decreased 
availability of acetyl-CoA, NADH+H+ and ATP that will sustain glucose and ketone bodies 
production, conducing to hypoketotic hypoglycemia. Another consequence of the 
decreased availability of acetyl-CoA and ATP is hyperammonaemia. In the myocardium, 
that even in the feed state relies mainly on the oxidation of FA to get energy, FAO 
blockage conducte to an alternative use of glucose that will lead to a profound, but poorly 
understood, remodelling that results in the hypertrophy of the myocardium (Ritchie and 
Delbridge 2006). In the skeletal muscle, decrease of FAO will result in hypotonia, muscle 
weakness and exercise intolerance (Olpin 2013). 
2-Accumulation of toxic metabolites 
Defects in the FAO pathway result in the accumulation of several intermediates from the 
pathway. These intermediates can be toxic by themselves or further metabolised to toxic 
derivates (Olpin 2013).  
In MCADD, octanoyl-CoA has been reported to illicit oxidative damage, reduce glutathione 
reserves and inhibit cytochrome c activity (Schuck, Ferreira Gda et al. 2009); octanoic 
acid leads to inhibition of choroid plexus organic anion transport(Kim, Roe et al. 1992); 
decanoic acid accumulation results in uncouple OXPHOS (Schuck, Ferreira et al. 2009) 
and inhibition of complexes I-III, II-III and IV in rat liver (Scaini, Simon et al. 2012) while 
cis-4-decanoic acid uncouple OXPHOS in rat brain (Schuck, Ferreira Gda et al. 2010). 
The accumulation of long-chain acylcarnitines observed in CPT2, CACT and VLCADD, 
has the potential to inhibit n-acetylglutamate synthase (Mak, Kramer et al. 1986), 
contribute to Reactive Oxidative Species (ROS) formation, cause lipid peroxidation (that 
can cause cardiac arrhythmias) (Sparagna, Hickson-Bick et al. 2000). Also, accumulated 
long chain acyl-CoA’s present toxicity by causing the inhibition of OXPHOS (Ventura, 
Tavares de Almeida et al. 2007) and of the ATP/ADP carrier (Ventura, Ruiter et al. 2005). 
The best known example of toxic effects of accumulated metabolites in FAOD, are those 
associated to long-chain 3-hydroxy acylcarnitines and long-chain 3-hydroxy acyl-CoA’s 
that accumulate in MTP/LCHADD. They are the cause of the neuropathy and retinopathy 
that characterise these FAOD’s. Moreover 3-hydroxydodecanoic acid might interfere with 
Docosahexaenoic acid (DHA) metabolism in retinal pigment epithelium/neural membrane 
(Tein, Vajsar et al. 1999), and 3-hydroxytetradecanoic acid can uncouple OXPHOS (Tyni, 
Pourfarzam et al. 2002).  
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In MADD the accumulation of short, medium and long chain fatty acids is thought to be 
one of the ROS sources observed in this FAOD (Scaini, Simon et al. 2012). It is important 
to highlight that the accumulation of toxic metabolites in FAOD has the power to induce 
mitochondrial dysfunction and ROS generation. This is of particular relevance, because 
oxidative stress is for long related to cell signalling, survival and apoptosis being 
extensively associated to disease development (Hamanaka and Chandel 2010). 
3-Sequestration of vital components 
FAO blockage will result in the shortage of CoA, due to excess formation of acyl-CoA 
intermediates. As the mitochondrial pool of CoA is finite, this compromises several 
metabolic processes where CoA is involved.  
Another consequence of FAOD’s (with exception of CPT1) is the decreased availability of 
carnitine, which results in a diminished free carnitine plasma concentration. In cases of 
very pronounced carnitine depletion the transport of FA into mitochondria is compromised, 
not allowing their oxidation. This is the basis of the phenotype developed in CUD. 
Carnitine is also important as a detoxification element, which facilitates the removal of 
unmetabolised acyl groups from the mitochondria, avoiding their accumulation and 
contributing to the rescue of CoA (Olpin 2013). For these reasons carnitine depletion may 
contribute to disease development. 
4-Altered enzyme product 
In MTP/LCHAD defects the occurrence of acute respiratory distress syndrome (ARDS) 
has been reported (Lundy, Shield et al. 2003, Olpin, Clark et al. 2005). It is believed that 
mitochondrial dysfunction and surfactant abnormalities are the mechanisms underlying 
ARDS occurrence in MTP/LCHAD deficiencies (Suhrie, Karunanidhi et al. 2011). It was 
proposed that accumulated fatty acid derivatives might alter the phospholipids of the 
surfactant, impairing its function. Another hypothesis is that as 
palmitoylmyristoylphosphatidylcholine is a component of surfactant, fatty acid shortening 
is probably needed for its formation (Olpin 2013). 
5-Loss of protein/protein interaction 
The best-documented example of protein/protein  loss due to a FAOD is SCHADD. In this 
case the absence of SCHAD protein will conduce to the loss of its inhibitory effect over 
glutamate dehydrogenase, increasing its activity, which results in insulin overproduction 
(Li, Chen et al. 2010). Nevertheless, several protein interactions in the mitochondria have 
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been hypothesised (Gregersen and Olsen 2010), being expected the discovery and 
characterisation of more protein/protein interactions in FAOD in a near future. 
6-Accumulation of misfolded proteins 
The majority of mutations associated to FAOD are missense mutations (approximately 
two thirds) (Gregersen and Olsen 2010), that have the potential to not abolish mRNA 
expression/stability neither polypeptide biosynthesis, resulting in polypeptide with an 
abnormal conformation due to misfolding (Gregersen, Bross et al. 2006, Gregersen, 
Andresen et al. 2008, Gregersen and Olsen 2010). Besides missense mutations in exons, 
that alter aminoacids, some small in-frame deletions and insertions that result in additions 
or suppressions of one or more aminoacids can also be associated to protein misfolding 
(Gregersen and Olsen 2010).  
When misfolded proteins accumulate inside mitochondria (and for this to occur is 
important that the mutation doesn’t disrupt mitochondria leader sequence neither occur at 
exome splicing enhancer/silencers sites), they can undergo two distinct processes: 
degradation by the mitochondrial proteases that form the mitochondrial protein quality 
control system (mtPQC), or formation of protein aggregates (Pedersen, Bross et al. 2003, 
Pedersen, Kolvraa et al. 2008). In any of these processes mtPQC plays a key role since it 
is involved in the supervision of protein folding, counteracting aggregation and eliminating 
misfolded peptide chains before they can exert toxic effect, being this protecting ability 
dependent on internal and external factors (Gregersen, Bross et al. 2006).  
As consequence of a mutation that results in a variant misfolded protein, a loss of function 
will occur and will be noticed by a decrease of enzymatic activity, which is dependent on 
the nature of the mutation and other cellular/environmental determinants (as temperature 
or capacity of the mtPQC system). The accumulation of this misfolded protein results in 
the gain of function, that alongside with loss of the original function, will contribute to 
cellular dysfunction and disease phenotype (Gregersen, Bross et al. 2006, Gregersen and 
Olsen 2010). 
Several studies have related protein misfolding with the pathogenesis of FAOD. For 
example in MCADD many of the missense mutations found in the ACADM gene give 
origin to misfolded proteins (Maier, Gersting et al. 2009). In this disorder the highest levels 
of actanoilcarnitine are associated with the common missesse mutation p.Lys329Glu 
(c.985A>G), while in patients with other mutations levels are lower (Giak Sim, Carpenter 
et al. 2002, Maier, Liebl et al. 2005). It was also noticed that patients homozygous for the 
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common missense mutation present a high variability in the clinical phenotype, that 
ranges from a asymptomatic patients to others that present fatal attacks (Gregersen, 
Andresen et al. 2008). These two observations raised the hypothesis that the common 
missense mutation c.985A>G could result in a variable toxic gain of function (Gregersen, 
Andresen et al. 2008). It has been shown that the variant MCAD protein, due to the 
common mutation, is subject to misfolding (Bross, Andresen et al. 1993) and that its 
accumulation was temperature sensitive (Bross, Jespersen et al. 1995), being this a 
possible explanation for the clinical picture associated to febrile illness. 
Another FAOD where misfolding seems to play an important role in disease development 
is SCADD. Pathophysiological relevance of the genetic variations in ACADS gene stills on 
debate, as the clinical significance of the disease itself (Jethva and Ficicioglu 2008, 
Pedersen, Kolvraa et al. 2008). Nevertheless, studies of ACADS variants (that strangely 
are mostly caused by missense mutations, for which so far there is no definitive 
justification (Gregersen, Andresen et al. 2008)) showed that some conduct to the 
accumulation of misfolded proteins, resulting on mitochondrial fission and oxidative stress 
in some conditions (Schmidt, Corydon et al. 2010, Schmidt, Corydon et al. 2010). 
The fate of misfolded proteins depends on the nature of the gene variation, other genetic 
factors as well as cellular and environmental conditioners (Gregersen, Andresen et al. 
2008), with this complex relationships influencing and inducing variability in the 
genotype/phenotype relationship. Considering the actual knowledge, some cases of 
FAOD can be included in the group of conformational protein misfolded diseases. 
2.3.2 Oxidative stress and FAOD 
Accumulation of toxic metabolites and misfolded proteins are known to cause oxidative 
stress, being its participation on cell signalling and survival extensively explored and 
subject for numerous publications (Bolisetty and Jaimes 2013). Considering the known 
effects of oxidative stress in the pathophysiology of several disorders it is supposed that it 
also plays an important role on FAO disease development (Schmidt, Corydon et al. 2010, 
Olsen, Cornelius et al. 2013). 
It was back in 1984 when free radicals were described as “any species capable of 
independent existence that contains one or more impaired electrons” (Halliwell and 
Gutteridge 1984). The term ROS refers to a variety of reactive molecules derived from 
oxygen and can be free radical (superoxie – O2-), hydroxyl radical (OH) or non radicals as 
hydrogen peroxide (H2O2). On the other hand Reactive Nitrogen Species (RNS) are 
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derived from nitrogen and can be classified into ions (peroxynitrite – ONOO-) or non-ions 
(nitric oxide – NO) (Bolisetty and Jaimes 2013). 
Mitochondria is the main source of ROS in the cell, that are mainly produced as a 
consequence of electron leakage during the normal activity of the OXPHOS, being a side 
product of respiration (Turrens 2003, Murphy 2009). The main points of electron leak, in 
the electron transport chain are complex I (NADH ubiquinone oxidoreductase), complex II 
(succinate dehydrogenase) and complex III (ubiquinol cytochrome c reductase), and they 
will prematurely reduce oxygen and give origin to superoxide (Turrens 2003, Murphy 
2009). Another point of ROS production in mitochondria, with particular interest for FAOD 
is ETF complex (Rodrigues and Gomes 2012, Olsen, Cornelius et al. 2013). Other 
enzymes like glycerol-3-phospate dehydrogenase, monoamine oxidase and 
diidrolipoamide dehydrogenase are also sites for ROS generation, but to a less extent 
(Drahota, Chowdhury et al. 2002, Maurel, Hernandez et al. 2003, Miwa, St-Pierre et al. 
2003, Tretter and Adam-Vizi 2004, Seifert, Estey et al. 2010). 
Considering that low levels of superoxide are constantly produced during normal 
mitochondrial activity there are several pathways involved in detoxification of this ion. 
Cellular antioxidants, particularly mitochondrial antioxidants, can be divided into two 
groups: the enzymatic and the non-enzymatic ones. From the enzymatic group the most 
important is manganese superoxide dismutase (MnSOD) a mitochondrial matrix enzyme 
that catalyses the conversion of superoxide into hydrogen peroxide. Hydrogen peroxide is 
then converted to water by the action of catalase, glutathione peroxidase and 
peroxiredoxins. In the group of the non-enzymatic antioxidants are for example 
glutathione, ascorbic acid and α-tocopherol (Bolisetty and Jaimes 2013). 
Increased ROS generation as a consequence of mutations in proteins at the sites of ROS 
production (eg. MADD) (Rodrigues and Gomes 2012) or by secondary affection of the 
normal OXPHOS/mitochondrial function, will trigger a cascade of signalling pathways 
involved in inflammation, apoptosis, DNA repair, proliferation and cell cycle arrest 
(Bolisetty and Jaimes 2013). ROS also induces damage to mitochondria structures, like 
proteins and lipids, compromising its function (Bolisetty and Jaimes 2013). ROS are not 
only damaging to the mitochondria/cell, being also very important in signalling (mostly 
H2O2), namely in stress signalling and cell survival response (Hamanaka and Chandel 
2010, Olsen, Cornelius et al. 2013). 
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ROS increase can be subdivided into two classes: a milder increase that induces 
autophagy (or mitophagy), acting as a survival mechanism eliminating damaged 
structures; and higher ROS levels that alter signalling pathways to induce autophagic or 
apoptotic cell death(Chen, McMillan-Ward et al. 2008, Nishida, Yamaguchi et al. 2008). 
(figure 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8: ROS levels are crucial for biological outcome (adapted from (Hamanaka 
and Chandel 2010) ). 
Low ROS levels are essential for cellular processes such as cell proliferation or 
differentiation. ROS production will result in adaptive programs for cell survival as the 
trigger of antioxidant defences. Higher ROS levels will initiate senescence and apoptosis 
while very high ROS will result in a non-signalling, irreversible damage to cellular 
components. ROS, Reactive Oxygen Species. 
 
Besides the almost certain involvement of ROS in mitochondrial and cellular dysfunction 
in FAOD, the exact mechanisms by which ROS are produced and the consequences of its 
increase on phenotype still need to be addressed. 
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2.4. Laboratory approach to the diagnosis of fatty acid oxidation disorders. 
During many years the state of the art in the diagnosis of FAOD was the analysis of the 
organic acids excretion in urine and the measurement of total and free carnitine in blood. 
Organic acids analysis allows the detection of dicarboxilic aciduria (high excretion of 
adipic, suberic and sebacic acids) produced as a result of a β-oxidation block (Hoffmann 
and Feyh 2003). Dicarboxilic aciduria is a normal finding in healthy children as a response 
to fasting, but here with ketosis (in FAOD the sum of dicarboxilis acids is higher than the 
sum of the ketone bodies). In the organic acids analysis is also possible to detect more 
specific glycine conjugates formed as consequence of FAOD (ex. hexanoylglycine in 
MCAD deficiency) (Hoffmann and Feyh 2003). The problem with this approach was the 
poor specificity and sensitivity to detect FAOD, with organic acids profiles looking normal 
between episodes. Nevertheless, combining the information from the organic acids 
analysis with the clinical history and enzymatic activity measurements it was possible to 
diagnose of at least the most severe forms of FAOD. 
This scenario only changed in the 90’s with the advances in mass spectrometry, more 
precisely in tandem mass spectrometry (MS/MS), with a significant cost reduction and 
technical developments that conducted to a more reliable and easy operation This new 
generation of MS/MS analysis allows the quantification of acylcarnitines in several body 
fluids, in a way they could be progressively introduced in metabolic laboratories. The 
sensitivity and specificity of acylcarnitine analysis in blood (where free carnitine and many 
acyl-conjugates are quantified) in the diagnosis of FAOD is much higher than those 
previously delivered by organic acid analysis in urine, namely in the inter crises periods.  
The development of a new, more specific and sensitive method adapted to high 
throughput alongside with treatment efficacy in many of the FAOD, made this group of 
metabolic disorders a key target for Newborn Screening (NBS) programs. Since the 
publications of Millington in the 90’s (Millington, Kodo et al. 1990, Van Hove, Zhang et al. 
1993) that NBS programs all over the world have been introducing MS/MS in their daily 
practice, and nowadays the screening for FAOD is a reality in almost every developed 
country (Bodamer, Hoffmann et al. 2007). 
Acylcarnitine analysis and more precisely acylcarnitine analysis in blood spots as a NBS 
practice, completely changed the diagnostic approach of FAOD and revealed a new set of 
questions and a new reality in the natural history of this group of disorders. First, the 
combination of a more sensitive approach with NBS busted the number of patients with 
FAOD diagnoses. When disease incidence before and after NBS are compared, for some 
FAOD they clearly double (Wilcken, Haas et al. 2007). Secondly, the follow-up of the 
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patients detected by NBS revealed that some of them remain asymptomatic through life, 
and that their genotypes were different from those detected clinically (eg. MCADD) 
(Andresen, Dobrowolski et al. 2001, Andresen, Lund et al. 2012). So, the increased 
number of patients detected through NBS is due not only to the detection of severe forms 
that most probably died in the neonatal period without diagnosis, but also due to an 
increased sensitivity that allowed the detection of milder forms, in patients that would 
probably remain asymptomatic through life. Thirdly, very differently clinical progressions 
were observed in patients with the same genotype. This, alongside with continuing clinical 
and pathophysiological research, raised some new questions on the factors contributing to 
disease development in FAOD, some of which were clearly addressed by Gregersen and 
collaborators (Gregersen, Andresen et al. 2008). In this paper, the highlighted questions 
were: why 80% of symptomatic patients with MCAD deficiency are homozygous for the 
prevalent c.985A>G whereas this is found only in about 50% of the newborns detected by 
NBS?; What is the connection between variations in ETFDH gene in RR-MADD, and the 
observed deficiency of a number of different mitochondrial dehydrogenases as well as 
deficiency of FAD and Coenzyme Q10?; In SCAD deficiency, are ACDS gene variations 
disease-associated, especially combined with other genetic/cellular/environmental factors 
that may act synergistically? (Gregersen, Andresen et al. 2008) 
These and many other questions can be raised on FAOD, but are almost all related to the 
understanding of the mechanisms by which factors like the nature of the mutation, 
interaction with other genetic factors and interaction with cellular, environmental 
conditions and stressors, influence the phenotype at the protein, cellular and clinical level. 
Until now, most proposed theories are mainly speculative with little supporting 
experimental evidence, with little sustained knowledge on its pathophysiology, above all at 
a cellular level (Gregersen, Andresen et al. 2008, Olpin 2013) 
 
3. Aims of the study 
 
The general goals of this work are to better understand the epidemiology of FAOD in 
Portugal and Iberia as well as to increase the knowledge on the way mitochondrial adapts 
and responds to a blockage on fatty acid oxidation. To accomplish the second one, a 
global proteomic approach was used, since it gives us with a broad perspective on 
mitochondrial adaptation. 
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Five specific aims were defined: 
 
1. Characterise epidemiological parameters of FAOD in Portugal and in Iberia, to 
better understand their impact in health (study 1 and study 2); 
 
2. Compare different experimental approaches for the characterization of the 
mitochondrial proteome from Human fibroblasts, envisioning the characterisation 
of mitochondrial adaptation to FAOD (study 3); 
 
3. Characterization of mitochondrial proteome adaptation to a severe defect of ETF-
QO (study 4); 
 
4.  Evaluate the mitochondrial proteome adaptation to a defect in LCHAD (study 5); 
 
5. Compare the mitochondrial response to severe and mild defects of ETF-QO (study 
6); 
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General discussion 
 
Mitochondria fatty acid β-oxidation disorders are one of the main groups of inherited 
metabolic diseases alongside glycogen storage disease, organic acidurias, urea cycle 
defects and OXPHOS defects, only to cite some. Without an early intervention the 
majority of FAOD leads to high morbidity and mortality, which makes them key targets for 
NBS programs. 
Data from NBS programs allow a better comprehension of the natural history of these 
disorders being also, due to their high coverage and detection rate, one of the best ways 
to estimate the birth prevalence of a disorder or group of disorders. This epidemiological 
index is one of the important parameters to decide if a disease should or should not be 
included in screening programs, due to its impact in screening value (Andermann, 
Blancquaert et al. 2008). 
Since the beginning of the XXI century that NBS programs in Europe started to introduce 
MS/MS screening for metabolic disorders in their practice (Loeber, Burgard et al. 2012) 
and since then several reports on the birth prevalence of FAOD in European countries 
became available (Kasper, Ratschmann et al. 2010, Lindner, Gramer et al. 2011, Lund, 
Hougaard et al. 2012), all revealing MCADD as the most frequent FAOD. It also became 
clear that this group of metabolic disorders was much more frequent than previously 
expected based on clinical evaluation (Wilcken, Haas et al. 2007, Spiekerkoetter 2010). 
This is mostly due to the identification of patients that could remain asymptomatic or with 
minor symptoms throughout life and, on the other hand, to the detection of patients with 
severe forms that could die without diagnosis. Nevertheless, data from Iberia is scarce 
with the only report representing data from the NBS of about 300,000 Portuguese 
newborns (Vilarinho, Rocha et al. 2010). There was also no report integrating available 
data on birth prevalence of FAOD in Europe. In order to fulfil this gap, data from six 
Iberian NBS programs were collected (Portugal, Galicia, Aragon/LaRioja, Murcia, Western 
Andalucia and Eastern Andalucia) resulting in the compilation of the results from the 
screening of more than 1.6 million newborns, which was compared to available data from 
other European populations (study 1). Our data reveal that the global birth prevalence of 
FAOD in Iberia is one of the highest reported (1:7,914; 95% CI: 1:9,054 to 1:6,916) in line 
with Denmark (1:7,691) (Lund, Hougaard et al. 2012) and Italy (1:8,777) (data extracted 
from Italian national NBS reports from 2006 to 2012, available on 
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http://www.simmesn.it/it/documents/rt_screening/index.html; accessed on December 
2013) and much higher than the observed in Austria and Greece (1:12,704 and 1:45,000 
respectively) (Kasper, Ratschmann et al. 2010, Loukas, Soumelas et al. 2010). However, 
significant differences were also noticed between Iberian regions, with Portugal presenting 
higher birth prevalence of FAOD than Spain. Portugal with a birth prevalence of FAOD of 
1:6,351 newborns, almost the double of Spain (1:12,104), has one of the highest birth 
prevalence of FAOD ever reported. The major contributor for this result is the high 
frequency of MCADD in Portugal that presents a birth prevalence of 1:8,380, one of the 
highest reported. The most probable explanation for this is the fact that the great majority 
of Portuguese MCADD patients are Gypsies, a community classically associated to high 
inbreeding. Overall, data highlight the importance of screening all Iberian newborns for 
this group of disorders. 
In order to understand better the relationship between genotype, biochemical parameters 
and clinical data at diagnosis and during follow up in MCADD patients, a multicenter 
research project was established between Portuguese and Spanish groups (study 2). 
Data from this project revealed that the percentage of MCADD patients homozygous for 
the common mutation c.985 A>G is 76% among the studied cohort and higher than 
previously reported for other populations, that range from 30% to 71% (Yokota, Coates et 
al. 1991, Nichols, Saavedra-Matiz et al. 2008). This is mostly due to the high occurrence 
of this disorder among Iberian Gypsy communities, particularly in Portugal, and represents 
an important epidemiological difference when in comparison with other European 
populations. It was also observed a statistically significant association between low free 
carnitine levels at the time of NBS and homozygosity for the common mutation. Although 
carnitine supplementation in MCADD patients is controversial (Walter 2003) this result 
points to the need of a different follow-up protocol depending on the genotype, with a tight 
monitoring of carnitine levels in homozygous for the common mutation. This study also 
contributed to a better understanding of the relationship between genotype and 
biochemical phenotype. Nevertheless, MCADD remains an unpredictable FAOD, 
indicating the need of further studies to disclose its pathophysiology. 
To go deeper into the pathophysiology of inherited metabolic disorders in general and of 
FAOD in particular, we have to look at them not as purely monogenic disorders and study 
them in a polygenic perspective. In order to achieve it, a global mitochondrial proteomic 
approach was applied to mitochondria extracts obtained from FAOD patients’ fibroblasts. 
Mitochondrial proteomics allows disclosing mitochondrial dynamics under various 
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pathophysiological conditions and provides an integrated perception into mitochondrial 
protein relative abundance, highlighting pathways activation/inhibition. 
Although liver, heart and skeletal muscle are the most affected tissues in FAOD, skin 
fibroblasts are usually the sample of choice for the enzymatic confirmation of diagnosis, 
being also a model system for the study of disease pathogenesis (Palmfeldt, Vang et al. 
2009, Gregersen, Hansen et al. 2012). Fibroblasts are an attractive sample considering 
the minimal invasive character of sampling and the large amount of cell material that can 
be obtained by culturing. Besides these advantages very few studies focused on 
mitochondrial protein profiling in cultured fibroblasts were reported. In order to define the 
strengths and limitations of a proteomic approach to the study of mitochondrial proteome 
in fibroblasts and the potential implications for the comprehension of metabolic disease 
pathogenesis, a comparative analysis of gel-based and gel-free protein approaches and 
protein identification algorithms (Mascot and Paragon) was performed (study 3). Three 
separation approaches were compared: two dimensional electrophoresis (2DE-MS), 
sodium dodecyl-sulphate liquid chromatography (SDS-LC-MS) and multidimentional liquid 
chromatography (2D-LC-MS), followed by mass spectrometry analysis for protein 
identification. The combined data from all these approaches and search methods allowed 
the identification of 696 non-redundant proteins. Despite the high sample amount needed 
for 2DE, approximately six times more than for SDS-LC or 2D-LC, fewer proteins were 
identified in comparison with the other two separation methods. However, 2DE allows 
distinguishing multiple forms of proteins with differences in molecular mass, isoelectric 
point and with post-transcriptional modifications (PTM’s) (e.g. phosphorylation). Data 
highlighted the impact of protein separation methods on the characterization of 
mitochondrial proteome from cultured fibroblasts. Although the higher number of proteins 
identified by SDS-LC, 2DE allows the identification of a significant content of unique 
proteins and so must be seen as a complementary approach for a deeper protein profiling 
of mitochondria. The results show the power of integrating different separation 
technologies and protein identification algorithms. 
To describe the mitochondrial proteome response to FAOD, fibroblasts from patients with 
MADD (severe and moderate forms, all with mutations in ETFDH gene and non 
responsive to riboflavin) and LCHADD (homozygous for the common mutation) were 
chosen. The choice of these disorders was based on the possibility of analysing two 
groups – mild and severe – that could potentiate the discriminatory power on the 
mitochondrial response to different deficiency degrees, enabling also comparisons 
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between them, looking for similarities and differences. The generated data could then be 
compared to that reported for less severe FAOD. 
The characterization of mitochondrial proteome of a severe MADD by 2DE-MS/MS 
allowed the identification of 286 distinct proteins from several functional clusters, with 
particular relevance to protein binding/folding, metabolism and apoptosis (study 4). The 
main observed differences in protein abundance included the overexpression of 
chaperones (e.g. Hsp 60 and Hsp 70), antioxidant enzymes (e.g. MnSOD and 
peroxiredoxin-6), apoptotic proteins (e.g. Girdin) and glycolytic enzymes (e.g. 
glyceraldeyde-3-phospate dehydrogenase (GAPDH and α-enolase), alongside a down-
representation of some β-oxidation enzymes (e.g. MCAD and SCAD). 
The obtained data reveals a cellular adaptation to the lack of energy production through β-
oxidation of fatty acids with a shift to glycolysis, represented by an overrepresentation of 
glycolytic enzymes and down-representation of β-oxidation ones. Another relevant finding 
was the down-representation of some OXPHOS related proteins (e.g. ATP synthase α 
and β, and NADH dehydrogenase flavoprotein 2), which highlights the close link between 
OXPHOS and FAO, at least in ETF complex defects. ATP synthase activity was 
decreased, being most probably OXPHOS secondary dysfunction a contributor for the 
pathophysiology in ETF complex deficiencies. The overexpression of chaperones 
probably reflects a cellular response to counteract the instability/disorganization inside the 
mitochondria due to the absence of ETF-QO, with the consequent activation of the 
mtPQC system. The observed over-expression of mitochondrial antioxidant enzymes, like 
MnSOD, glutathione-S-transferase or peroxiredoxin-6, was most probably triggered by the 
increased ROS observed in these cells. Nevertheless, the presence of an increased 
quantity of apoptotic proteins, points out that cellular aggressors overwhelm cellular 
capacity to neutralize and control them, resulting in mitochondrial/cellular damage and 
ultimately in cellular death. 
In order to trace a pattern of mitochondrial response to LCHADD we proceed to the 
mitochondrial proteome analysis of one severe and one mild LCHADD patients (study 5). 
The obtained results revealed that as in severe MADD, there is a metabolic shift to 
glycolysis in response to the FAO blockage, with an overrepresentation of glycolytic 
enzymes. Signs of apoptosis were also noticed, like the overrepresentation of cofilin, 
whose translocation to the mitochondria is an early step in apoptosis induction, occurring 
before caspase activation (Chua, Volbracht et al. 2003). The comparison of mitochondrial 
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proteome between both patients highlighted a different regulation of the antioxidant 
defence system. The patient with the severe clinical phenotype presented an over-
expression of MnSOD associated with a significant increase in ROS levels, while the mild 
LCHADD patient presented slightly ROS elevation and MnSOD down-regulation. This was 
particularly interesting since both patients were homozygous for the same disease 
causing mutation. Probably in individuals with lower ROS levels there is the need for a 
MnSOD down-regulation so they can increase and act as signalling molecules driving the 
metabolic reprogramming, while in the forms with high ROS, MnSOD must be up-
regulated for detoxifying purposes. These results suggest that mitochondrial ROS levels 
and the individual ability to buffer them are of key importance for disease progression and 
outcome. It also becomes clear that other determinants than the disease causing mutation 
modulate the distinct clinical outcomes of LCHADD patients. 
When a comparison between severe (S:MADD) and mild (M:MADD; non-riboflavin 
responsive) MADD forms was made (study 6) a metabolic reprogramming towards 
glycolysis and apoptotic pathway modulation was observed in all patients. Nevertheless, 
such adaptation was more notorious in S:MADD than in M:MADD with a more pronounced 
positive modulation of the apoptotic process. In respect to antioxidant system regulation, 
in all three patients an MnSOD up-regulation was observed. ROS levels in M:MADD seem 
to be high enough to trigger a MnSOD overexpression. Howerver, ROS levels in M:MADD 
are expected to be lower than in S:MADD based on the less apoptotic signs and on the 
lower levels of glyceraldehyde-3-phosphate dehydrogenase, a signalling component of 
oxidative stress cell death (Ito, Pagano et al. 1996, Chen, Zhan et al. 2011). These 
alterations in ROS levels probably underlie the differences in apoptotic pathway 
modulation, contributing to the clinical phenotype. 
Merging the data from MADD and LCHADD it is possible to trace similarities in the 
response mechanisms of mitochondria to a FAO blockage. It was observed in all patients 
a metabolic reprogramming towards glycolysis – the Warburg effect. This was also 
reported recently in SCADD patients (Edhager, Stenbroen et al. 2014) which points out 
that it is a hallmark of FAOD, independently of the enzyme deficiency and of disease 
severity. While in cancer cells the Warburg effect aims at rapidly generating ATP, 
molecular precursors and NADPH to support cell proliferation, in FAO it seems to be a 
cellular adaptation to dysfunctional mitochondria, in order to increase survival. The 
Warburg effect may result from the activation of the transcription factor hypoxia-inducible 
factor 1-alpha (HIF 1α). A down regulation of prolyl 4 hydroxylase, which prompts to a 
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decrease HIF 1α degradation, was observed in LCHADD. Moreover, it has been proposed 
that ROS are also responsible for HIF 1α stimulation (Nazarewicz, Dikalova et al. 2013, 
Olsen, Cornelius et al. 2013). This links the observed oxidative stress, mitochondrial 
antioxidant system modulation and pro-survival metabolic reprogramming.  
The data here obtained and that reported by others (Pedersen, Zolkipli et al. 2010, 
Schmidt, Corydon et al. 2010, Olsen, Cornelius et al. 2013) allows to hypothesise a 
mechanism for MnSOD modulation in FAOD (figure 1).  
 
 
 
 
 
 
 
 
 
Figure 1: Hypothetical model for the modulation of MnSOD in FAOD.  
According to this hypothetical model, in FAOD cells with lower ROS levels there is a 
down-regulation of MnSOD so they can increase and act as signalling molecules, and 
when ROS levels are higher MnSOD is over-expressed for detoxifying purposes. 
N, normal; MnSOD, manganese superoxide dismutase; ROS, reactive oxygen species. 
It is probable that due to a FAO blockage, and to the resulting mitochondrial dysfunction, 
cells shift to glycolysis for ATP production being ROS a key signalling in this process 
(Nazarewicz, Dikalova et al. 2013). In FAOD cells that due to the nature of the enzyme 
deficiency, the nature of the disease causing mutation or individual response to stress, 
have lower oxidative stress levels, MnSOD is down-regulated in order to increase ROS, 
namely superoxide which was suggested to be a signalling molecule towards Warburg 
effect (Sarsour, Kalen et al. 2012, Nazarewicz, Dikalova et al. 2013). On the other hand, 
when FAO deficient mitochondria already generate significant amounts of ROS, cell 
overexpress MnSOD for detoxifying purposes, which can lead to cellular death when ROS 
ROS N/ ROS ROS 
MnSOD MnSOD MnSOD 
Disease severity 
Pro-survival 
! 147!
levels are very high (Bolisetty and Jaimes 2013). According to this hypothesis low ROS-
inducing MnSOD down-regulation are more favourable than high ROS and MnSOD 
overexpression. This hypothetical model on the possible contribution of ROS for 
pathophysiology of FAOD might help to explain why individuals with the same disease 
causing mutation may present divergent clinical pictures, based on ROS levels generated 
by their mitochondria. Nevertheless, more data is needed to corroborate the proposed 
hypothesis. 
It is important to keep in mind that, although important, ROS are only part of the players 
that contribute to disease development in FAOD. Due to the combination and relation 
between genetic, epigenetic and environmental factors, the initial genetic mutation that 
leads to a defect on the function of a FAO enzyme may be seen as a risk factor for 
developing disease. Risk level depends on the deficient enzyme, the nature of the 
mutation itself, individual cellular response capacity and environmental factors (as fever or 
fasting), being the risk higher in disorders affecting the oxidation of long chain FA and 
lower in those affecting the oxidation of medium and short chain fatty acids.  !
!
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Conclusions 
 
Mitochondrial fatty acid β-oxidation disorders are a group of inherited metabolic diseases 
in which some epidemiological parameters (including birth prevalence) are not estimated 
for Iberia, and in which mitochondrial dysfunction is believed to play a critical role in its 
pathophysiology; however the mechanisms involved are not disclosed. To give new 
insights on these issues, NBS data was collected within an Iberian collaboration and 
mitochondrial proteome profiling of fibroblasts obtained from FAOD patients, namely 
MADD and LCHADD, was performed. Data obtained allowed to conclude that: 
i. FAOD presents in Iberia one of the highest birth prevalence comparing with other 
European countries. Particularly in Portugal, FAOD has one of the highest values 
ever reported, mainly due to the high birth prevalence of MCADD. This data 
highlights the importance and impact of this group of disorders in this European 
region. 
ii. Mitochondrial proteome response in severe MADD forms reflects a metabolic shift 
from FAO to glycolysis (Warburg effect) and shows an over-expression of mtPQC 
system components and antioxidant enzymes, probably trying to counteract the 
instability/disorganization on the mitochondria and increased ROS. The over-
representation of apoptotic proteins seems to reflect an overwhelmed cellular 
defence capacity, resulting in cell death. 
iii. In LCHADD fibroblast cell lines the observed mitochondrial response is much like 
the one observed in severe MADD, with over-expression of glycolytic enzymes 
and apoptosis related proteins alongside with antioxidant defence system 
modulation. Severe LCHADD present high ROS levels with MnSOD over-
expression while moderate forms present lower ROS and MnSOD down-
regulation, highlighting the contribution of oxidative stress and MnSOD modulation 
for the phenotype. 
iv. The comparison between severe and moderate MADD forms does not reveal 
major differences in the pathways involved in mitochondrial response neither in 
MnSOD modulation. Most probably ROS are high enough to trigger a 
mitochondrial response similar to severe MADD. 
In overall, experimental findings presented in this thesis highlight the significant birth 
prevalence of FAOD in Iberia and particularly in Portugal. It also allows tracing, for the first 
time, a pattern of mitochondrial response to FAOD blockages with a key metabolic 
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reprogramming towards glycolysis and antioxidant defence system modulation. Data also 
support the growing idea of ROS as a keystone in cellular pathophysiology of FAOD. 
Future studies focused on how metabolic shifting and antioxidant defence systems are 
regulated and contribute to disease in distinct FAOD will not only contribute for a better 
prediction of disease progression and severity but will also open possibilities to establish 
and develop new therapeutic strategies.  
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APPENDIX – Supplementary data 
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Study 2- Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: 
regional experience and high incidence of carnitine deficiency. 
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Table S1. Summary of levels of acylcarnitines at diagnosis, mutations, carnitine free levels, 
treatment and evolution of MCADD patients. 
CV: control values; FS: Free of Symptoms; MD: Metabolic decompensation; n.d.= not done; n.f: not 
found in this moment  m: month; y: year; bs (blood spot samples); ps (plasma samples)  *All 
mutations were named according to the nucleotide change. 
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Study 3 - Mitochondria proteome profiling: A comparative analysis between gel- and gel-
free approaches. 
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Supplemental figure S1: Immunobloting analysis of mitochondrial fraction and cell extract, 
evidencing the successful enrichment of mitochondria from cultured fibroblasts.
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Supplemental figure S2: Gene Ontology Analysis for subcellular location of identified 
proteins using the ClueGo bioinformatic tool. 
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Supplemental figure S3: Hierarchical representation of BiNGO analysis, in terms of biological processes based on all identified proteins in 
isolated mitochondria 
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Supplemental table S1: Proteins identified using Mascot 2D-LC! !!
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Supplemental table S2: Proteins identified using Mascot SDS-LC!
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Supplemental table S3: Proteins identified using Protein Pilot 2D-LC !
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Supplemental table S4: Proteins identified using Protein Pilot SDS-LC!!!
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Study 4- Characterization of mitochondrial proteome in a severe case of ETF-QO 
deficiency. 
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Supplemental table S1: Total proteins identified in the MADD patient. 
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Supplemental figure S1 – Cluster analysis of identified proteins in functional clusters 
(according to Gene Ontology Annotation Database – GOA). 
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Supplemental figure S2: Differentially expressed proteins grouped according to Biological 
process (A) and Molecular function (B) (assigned by Panther). 
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Study 5- Unravelling the impact of long-chain 3-hydroxyacyl-CoA dehydrogenase 
deficiency on mitochondrial proteome. 
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!
Supplemental figure S1 – (A) String analysis of the interaction of MTP α-subunit 
(ECHA_HUMAN), (B) Metabolic processes associated with MTP α-subunit according to 
G.O. 
ECHA_HUMAN)
A"
B"
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Supplemental table S1 – Primers sequences  
 
Primer Sequence  
MT-ND1-F            CCCTAAAACCCGCCACATCT 
MT-ND1-R            GAGCGATGGTGAGAGCTAAGGT 
MT-ND4-F            CCATTCTCCTCCTATCCCTCAAC 
MT-ND4-R            CACAATCTGATGTTTTGGTTAAACTATATTT 
18S rRNA-F         GGCGTCCCCCAACTTCTTA 
18S rRNA-R        GGGCATCACAGACCTGTTATTG 
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Supplemental table S2A – List of proteins identified by nanoLC-MS/MS. !
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Supplemental table S2B - Differentially expressed proteins identified by comparative 
analysis of mitochondrial fraction of each of the patients studied with control subjects by 
nanoLC-MS/MS with iTRAQ labeling. !
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Study 6- Disclosing the differences in mitochondrial pathway modulation between severe 
and mild multiple acyl-CoA dehydrogenation deficiencies. 
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Supplemental table S1 – List of proteins identified by nanoLC-MS/MS. !
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